炎症环境下胆管反应与肝细胞癌术后预后关系的研究
|
摘要
第一部分：癌旁胆管反应与临床及病理学关系的研究
目的：评估癌旁胆管反应与临床病理资料间的关系。
方法：收集2001年1月到2003年6月期间第二军医大学附属东方肝胆外科医院原发性肝细胞癌根治性手术后病理标本106例。运用免疫组织化学方法检测癌旁胆管反应情况。整理肝细胞癌患者的临床及随访资料，分析癌旁胆管反应与肝细胞癌患者临床病理特征的关系。
结果：癌旁胆管反应的程度与肿瘤患者血清AFP水平（p=0.01）、血清ALT (p=0.017)、血清ALP (p=0.007)、血清HBsAg (+)(p=4.9E-4)、肿瘤包膜(p=0.027)、肿瘤个数(p=0.004)、镜下血管侵犯(p=0.031)、早期复发(p=0.010)、BCLC分期(p=0.003)和TNM分期（p=0.002）显著相关。
结论：癌旁组织中胆管反应的程度与肝细胞癌患者临床病理中肿瘤强侵袭性指标显著相关，癌旁胆管反应高的肿瘤表现出更强的侵袭性。
第二部分：癌旁胆管反应与肝癌根治性切除术后预后关系的研究
目的：分析肝细胞癌根治性切除术后预后的影响因素。
方法：回顾性分析2001年1月到2003年6月期间第二军医大学附属东方肝胆外科医院106例肝细胞癌根治性手术患者临床资料。采用Log-rank法检验进行统计学比较，寿命表法进行生存率分析，运用Cox比例风险模型进行多因素分析。
结果：全组患者1、3、5及7年总体生存率分别为71.7%、36.8%、32.1%及20.8%。多因素分析发现，肿瘤大小(﹥5vs≤5cm)、胆管反应（<2vs≥2）和BCLC分期(0/Avs B/C)是影响总生存的独立预后因素（p值分别为1.3E-04、9.3E-06及2.3E-04）。全组患者1、3、5及7年无瘤生存率分别为54.7%、24.5%、19.8%及8.5%。多因素分析发现，肿瘤大小(﹥5/≤5cm)、胆管反应（<2vs≥2）、TNM分期（I vs II/III）和炎症坏死分级(<9vs≥9)是影响无瘤生存的独立预后因素(p值分别为0.031、0.008、8.8E-06及0.023)。
结论：癌旁胆管反应程度是影响肝癌患者术后总生存、无瘤生存的独立预后因素。
第三部分：癌旁胆管反应与肝脏炎症坏死及肝硬化关系的研究
目的：探讨癌旁胆管反应与肝脏炎症坏死及肝硬化的相关性。
方法：收集2001年1月到2003年6月期间第二军医大学附属东方肝胆外科医院原发性肝细胞癌根治性手术后病理标本106例。运用免疫组织化学方法检测癌旁非肿瘤肝脏组织中胆管反应的水平，HE染色评价癌旁肝脏组织中炎症坏死及肝硬化情况，并对二者进行相关性分析。
结果：癌旁胆管反应程度与癌旁肝脏炎症坏死及肝硬化情况有相关性。癌旁组织中高水平胆管反应的肝癌患者其癌旁肝脏炎症坏死及肝硬化相对较重（r=0.563, p=3.4E-10；r=0.435, p=3.1E-06）。
结论：癌旁胆管反应与肝脏炎症坏死及肝硬化程度呈正相关，肝脏的炎症环境可能促进了胆管反应的升高。
第四部分：癌旁胆管反应与肝癌细胞的EpCAM表达关系的研究
目的：探讨癌旁胆管反应与肝癌细胞的EpCAM表达的相关性。
方法：收集2001年1月到2003年6月期间第二军医大学附属东方肝胆外科医院原发性肝细胞癌根治手术后病理标本106例。运用免疫组织化学方法检测癌旁胆管反应的水平和肝癌细胞的EpCAM表达情况，并对二者进行相关性分析。
结果：癌旁胆管反应与肝癌细胞的EpCAM的表达有密切相关性。癌旁组织中高水平胆管反应的肝癌患者其癌细胞的EpCAM表达也比较高（p=0.016）。
结论：癌旁胆管反应与肝癌细胞的EpCAM表达呈正相关，癌旁胆管反应可能与肝脏祖细胞的激活、增殖有关。
PartⅠStudy on the correlation between peritumoral DR andclinicopathology in hepatocellular carcinoma
Objective: To evaluate the peritumoral ductular reaction (DR) in hepatocellularcarcinoma (HCC), and its relationship with the clinicopathological features.
Methods: The clinicopathological features and DR were analyzed in106HCCpatients who received curative hepatectomy at the Eastern Hepatobiliary SurgeryHospital from January2001to June2003. Follow-up was completed in December2009. DR was performed by immunohistochemical analysis on peritumoral tissuesections. Relationship between peritumoral DR and clinicopathological features wasperformed by statistical analysis.
Results: Increased DR correlated with advanced BCLC stage (p=0.003), TNMstage (p=0.002), with elevated serum ALT (p=0.017), ALP (p=0.007), AFP (p=0.010) and HBsAg (+)(p=4.9E-4). Increased DR was also tended to correlate withmultiple nodules (p=0.004), absence of tumor capsule (p=0.027), severemicroscopic vascular invasion (p=0.031) and early recurrence (p=0.010).
Conclusions：Significantly peritumoral DR correlated with aggressive clinico-pathological features. It plays a critical role in the aggressiveness of HCC.
PartⅡPeritumoral ductular reaction and survival analysis of hepato-cellular carcinoma after hepatectomy
Objective: To appraise the relationship of risk factors with poor overall survivaland recurrence free survival in hepatocellular carcinoma after curative hepatectomy.
Methods: The clinicopathological characteristics and DR was analyzed in106HCC patients who received curative hepatectomy at the Eastern HepatobiliarySurgery Hospital from Junuary2001to June2003. The Kaplan–Meier method wasused in overall survival rates and recurrence free survival rates. The Log-Rank testwas used in survival curves. Variables were subjected to multivariate Cox regressionmodeling using forward stepwise variable selection when they with p <0.05inunivariate analysis.
Results: The1-,3-,5-,7-year RFS and OS rates were54.7%,24.5%,19.8%,8.5%and71.7%,36.8%,32.1%,20.8%respectively. Both DR and tumor size wereindependent prognostic factors for RFS and OS. DR was associated with elevatedrisks of recurrence (HR=2.380,95%CI=1.250-4.534, p=0.008) and death (HR=4.294,95%CI=2.255-8.177, p=9.3E-06). Tumor size was associated with elevatedrisks of recurrence (HR=1.804,95%CI=1.057-3.080, p=0.031) and death (HR=2.950,95%CI=1.694-5.137, p=1.3E-04). Besides, TNM and necroinflammatorygrade were demonstrated as independent predictors for RFS; while BCLC stage wasindependent prognostic factors for OS.
Conclusions：Peritumoral DR is an independent factor which affects overallsurvival and recurrence free survival of HCC.
PartⅢStudy on the correlation between peritumoral DR andNecroinflammatory grade, Fibrotic stage
Objective: To evaluate association between the peritumoral DR andnecroinflammatory grade, fibrotic stage in the non-tumor liver tissue.
Methods: The pathological specimens of liver tissues were obtained from106HCC patients who received curative hepatectomy at the Eastern HepatobiliarySurgery Hospital from January2001to June2003. Peritumoral DR was performed byimmunohistochemical analysis, necroinflammatory grade and fibrotic stage innon-tumor liver sections were scored by H&E. Association between peritumoral DRand necroinflammatory grade, fibrotic stage was performed by statistical analysis.
Results: The relationship of peritumoral DR and necroinflammatory grade,fibrotic stage was found significantly. Peritumoral DR significantly correlated withnecroinflammatory grade (r=0.563, p=3.4E-10) and fibrotic stage (r=0.435, p=3.1E-06) in HCC patients.
Conclusions： A necroinflammatory microenvironment perhaps promotedperitumoral ductular reactions in HCC.
PartⅣStudy on the correlation between peritumoral DR and tumoralEpCAM expression
Objective: To evaluate the peritumoral DR in the non-tumor liver tissue and itsrelationship with expression of tumoral EpCAM in HCC.
Methods: The pathological specimens of liver tissues were obtained from106HCC patients who received curative hepatectomy at the Eastern HepatobiliarySurgery Hospital from January2001to June2003. Peritumoral DR and tumoralEpCAM was performed by immunohistochemical analysis on non-tumoral liversections and tumoral tissues. Association between peritumoral DR and tumoralEpCAM expression was performed by statistical analysis.
Results: The relationship of peritumoral DR and tumoral EpCAM expressionwas found significantly. Elevated peritumoral DR was closely associated with tumoralEpCAM expression in HCC patients (p=0.016).
Conclusions：Elevated peritumoral DR was closely associated with tumoralEpCAM expression in HCC. Peritumoral DR was perhaps associated activation andproliferation of hepatic progenitor cell in HCC.
目的：评估癌旁胆管反应与临床病理资料间的关系。
方法：收集2001年1月到2003年6月期间第二军医大学附属东方肝胆外科医院原发性肝细胞癌根治性手术后病理标本106例。运用免疫组织化学方法检测癌旁胆管反应情况。整理肝细胞癌患者的临床及随访资料，分析癌旁胆管反应与肝细胞癌患者临床病理特征的关系。
结果：癌旁胆管反应的程度与肿瘤患者血清AFP水平（p=0.01）、血清ALT (p=0.017)、血清ALP (p=0.007)、血清HBsAg (+)(p=4.9E-4)、肿瘤包膜(p=0.027)、肿瘤个数(p=0.004)、镜下血管侵犯(p=0.031)、早期复发(p=0.010)、BCLC分期(p=0.003)和TNM分期（p=0.002）显著相关。
结论：癌旁组织中胆管反应的程度与肝细胞癌患者临床病理中肿瘤强侵袭性指标显著相关，癌旁胆管反应高的肿瘤表现出更强的侵袭性。
第二部分：癌旁胆管反应与肝癌根治性切除术后预后关系的研究
目的：分析肝细胞癌根治性切除术后预后的影响因素。
方法：回顾性分析2001年1月到2003年6月期间第二军医大学附属东方肝胆外科医院106例肝细胞癌根治性手术患者临床资料。采用Log-rank法检验进行统计学比较，寿命表法进行生存率分析，运用Cox比例风险模型进行多因素分析。
结果：全组患者1、3、5及7年总体生存率分别为71.7%、36.8%、32.1%及20.8%。多因素分析发现，肿瘤大小(﹥5vs≤5cm)、胆管反应（<2vs≥2）和BCLC分期(0/Avs B/C)是影响总生存的独立预后因素（p值分别为1.3E-04、9.3E-06及2.3E-04）。全组患者1、3、5及7年无瘤生存率分别为54.7%、24.5%、19.8%及8.5%。多因素分析发现，肿瘤大小(﹥5/≤5cm)、胆管反应（<2vs≥2）、TNM分期（I vs II/III）和炎症坏死分级(<9vs≥9)是影响无瘤生存的独立预后因素(p值分别为0.031、0.008、8.8E-06及0.023)。
结论：癌旁胆管反应程度是影响肝癌患者术后总生存、无瘤生存的独立预后因素。
第三部分：癌旁胆管反应与肝脏炎症坏死及肝硬化关系的研究
目的：探讨癌旁胆管反应与肝脏炎症坏死及肝硬化的相关性。
方法：收集2001年1月到2003年6月期间第二军医大学附属东方肝胆外科医院原发性肝细胞癌根治性手术后病理标本106例。运用免疫组织化学方法检测癌旁非肿瘤肝脏组织中胆管反应的水平，HE染色评价癌旁肝脏组织中炎症坏死及肝硬化情况，并对二者进行相关性分析。
结果：癌旁胆管反应程度与癌旁肝脏炎症坏死及肝硬化情况有相关性。癌旁组织中高水平胆管反应的肝癌患者其癌旁肝脏炎症坏死及肝硬化相对较重（r=0.563, p=3.4E-10；r=0.435, p=3.1E-06）。
结论：癌旁胆管反应与肝脏炎症坏死及肝硬化程度呈正相关，肝脏的炎症环境可能促进了胆管反应的升高。
第四部分：癌旁胆管反应与肝癌细胞的EpCAM表达关系的研究
目的：探讨癌旁胆管反应与肝癌细胞的EpCAM表达的相关性。
方法：收集2001年1月到2003年6月期间第二军医大学附属东方肝胆外科医院原发性肝细胞癌根治手术后病理标本106例。运用免疫组织化学方法检测癌旁胆管反应的水平和肝癌细胞的EpCAM表达情况，并对二者进行相关性分析。
结果：癌旁胆管反应与肝癌细胞的EpCAM的表达有密切相关性。癌旁组织中高水平胆管反应的肝癌患者其癌细胞的EpCAM表达也比较高（p=0.016）。
结论：癌旁胆管反应与肝癌细胞的EpCAM表达呈正相关，癌旁胆管反应可能与肝脏祖细胞的激活、增殖有关。
PartⅠStudy on the correlation between peritumoral DR andclinicopathology in hepatocellular carcinoma
Objective: To evaluate the peritumoral ductular reaction (DR) in hepatocellularcarcinoma (HCC), and its relationship with the clinicopathological features.
Methods: The clinicopathological features and DR were analyzed in106HCCpatients who received curative hepatectomy at the Eastern Hepatobiliary SurgeryHospital from January2001to June2003. Follow-up was completed in December2009. DR was performed by immunohistochemical analysis on peritumoral tissuesections. Relationship between peritumoral DR and clinicopathological features wasperformed by statistical analysis.
Results: Increased DR correlated with advanced BCLC stage (p=0.003), TNMstage (p=0.002), with elevated serum ALT (p=0.017), ALP (p=0.007), AFP (p=0.010) and HBsAg (+)(p=4.9E-4). Increased DR was also tended to correlate withmultiple nodules (p=0.004), absence of tumor capsule (p=0.027), severemicroscopic vascular invasion (p=0.031) and early recurrence (p=0.010).
Conclusions：Significantly peritumoral DR correlated with aggressive clinico-pathological features. It plays a critical role in the aggressiveness of HCC.
PartⅡPeritumoral ductular reaction and survival analysis of hepato-cellular carcinoma after hepatectomy
Objective: To appraise the relationship of risk factors with poor overall survivaland recurrence free survival in hepatocellular carcinoma after curative hepatectomy.
Methods: The clinicopathological characteristics and DR was analyzed in106HCC patients who received curative hepatectomy at the Eastern HepatobiliarySurgery Hospital from Junuary2001to June2003. The Kaplan–Meier method wasused in overall survival rates and recurrence free survival rates. The Log-Rank testwas used in survival curves. Variables were subjected to multivariate Cox regressionmodeling using forward stepwise variable selection when they with p <0.05inunivariate analysis.
Results: The1-,3-,5-,7-year RFS and OS rates were54.7%,24.5%,19.8%,8.5%and71.7%,36.8%,32.1%,20.8%respectively. Both DR and tumor size wereindependent prognostic factors for RFS and OS. DR was associated with elevatedrisks of recurrence (HR=2.380,95%CI=1.250-4.534, p=0.008) and death (HR=4.294,95%CI=2.255-8.177, p=9.3E-06). Tumor size was associated with elevatedrisks of recurrence (HR=1.804,95%CI=1.057-3.080, p=0.031) and death (HR=2.950,95%CI=1.694-5.137, p=1.3E-04). Besides, TNM and necroinflammatorygrade were demonstrated as independent predictors for RFS; while BCLC stage wasindependent prognostic factors for OS.
Conclusions：Peritumoral DR is an independent factor which affects overallsurvival and recurrence free survival of HCC.
PartⅢStudy on the correlation between peritumoral DR andNecroinflammatory grade, Fibrotic stage
Objective: To evaluate association between the peritumoral DR andnecroinflammatory grade, fibrotic stage in the non-tumor liver tissue.
Methods: The pathological specimens of liver tissues were obtained from106HCC patients who received curative hepatectomy at the Eastern HepatobiliarySurgery Hospital from January2001to June2003. Peritumoral DR was performed byimmunohistochemical analysis, necroinflammatory grade and fibrotic stage innon-tumor liver sections were scored by H&E. Association between peritumoral DRand necroinflammatory grade, fibrotic stage was performed by statistical analysis.
Results: The relationship of peritumoral DR and necroinflammatory grade,fibrotic stage was found significantly. Peritumoral DR significantly correlated withnecroinflammatory grade (r=0.563, p=3.4E-10) and fibrotic stage (r=0.435, p=3.1E-06) in HCC patients.
Conclusions： A necroinflammatory microenvironment perhaps promotedperitumoral ductular reactions in HCC.
PartⅣStudy on the correlation between peritumoral DR and tumoralEpCAM expression
Objective: To evaluate the peritumoral DR in the non-tumor liver tissue and itsrelationship with expression of tumoral EpCAM in HCC.
Methods: The pathological specimens of liver tissues were obtained from106HCC patients who received curative hepatectomy at the Eastern HepatobiliarySurgery Hospital from January2001to June2003. Peritumoral DR and tumoralEpCAM was performed by immunohistochemical analysis on non-tumoral liversections and tumoral tissues. Association between peritumoral DR and tumoralEpCAM expression was performed by statistical analysis.
Results: The relationship of peritumoral DR and tumoral EpCAM expressionwas found significantly. Elevated peritumoral DR was closely associated with tumoralEpCAM expression in HCC patients (p=0.016).
Conclusions：Elevated peritumoral DR was closely associated with tumoralEpCAM expression in HCC. Peritumoral DR was perhaps associated activation andproliferation of hepatic progenitor cell in HCC.
引文
.1. Zhou WP, Lai EC, Li AJ, Fu SY, Zhou JP, Pan ZY, Lau WY, Wu MC: Aprospective, randomized, controlled trial of preoperative transarterialchemoembolization for resectable large hepatocellular carcinoma. Ann Surg2009,249(2):195-202.
2. Llovet JM, Bruix J: Molecular targeted therapies in hepatocellular carcinoma.Hepatology2008,48(4):1312-1327.
3. Arciero CA, Sigurdson ER: Liver-directed therapies for patients with primaryliver cancer and hepatic metastases. Curr Treat Options Oncol2006,7(5):399-409.
4. Roskams T, Katoonizadeh A, Komuta M: Hepatic progenitor cells: an update.Clin Liver Dis2010,14(4):705-718.
5. Roskams TA, Theise ND, Balabaud C, Bhagat G, Bhathal PS, Bioulac-Sage P,Brunt EM, Crawford JM, Crosby HA, Desmet V et al: Nomenclature of thefiner branches of the biliary tree: canals, ductules, and ductular reactions inhuman livers. Hepatology2004,39(6):1739-1745.
6. Knight B, Matthews VB, Olynyk JK, Yeoh GC: Jekyll and Hyde: evolvingperspectives on the function and potential of the adult liver progenitor (oval)cell. Bioessays2005,27(11):1192-1202.
7. Libbrecht L, Desmet V, Van Damme B, Roskams T: Theimmunohistochemical phenotype of dysplastic foci in human liver: correlationwith putative progenitor cells. J Hepatol2000,33(1):76-84.
8. Durnez A, Verslype C, Nevens F, Fevery J, Aerts R, Pirenne J, Lesaffre E,Libbrecht L, Desmet V, Roskams T: The clinicopathological and prognosticrelevance of cytokeratin7and19expression in hepatocellular carcinoma. Apossible progenitor cell origin. Histopathology2006,49(2):138-151.
9. Yang XR, Xu Y, Yu B, Zhou J, Qiu SJ, Shi GM, Zhang BH, Wu WZ, Shi YH,Wu B et al: High expression levels of putative hepatic stem/progenitor cellbiomarkers related to tumour angiogenesis and poor prognosis ofhepatocellular carcinoma. Gut2010,59(7):953-962.
10. Roskams T: Liver stem cells and their implication in hepatocellular andcholangiocarcinoma. Oncogene2006,25(27):3818-3822.
11. Roskams T, Desmet V: Ductular reaction and its diagnostic significance.Semin Diagn Pathol1998,15(4):259-269.
12. Park YN, Kojiro M, Di Tommaso L, Dhillon AP, Kondo F, Nakano M,Sakamoto M, Theise ND, Roncalli M: Ductular reaction is helpful in definingearly stromal invasion, small hepatocellular carcinomas, and dysplasticnodules. Cancer2007,109(5):915-923.
13. Bateman AC, Hubscher SG: Cytokeratin expression as an aid to diagnosis inmedical liver biopsies. Histopathology2010,56(4):415-425.
14. Knight B, Matthews VB, Akhurst B, Croager EJ, Klinken E, Abraham LJ,Olynyk JK, Yeoh G: Liver inflammation and cytokine production, but notacute phase protein synthesis, accompany the adult liver progenitor (oval) cellresponse to chronic liver injury. Immunol Cell Biol2005,83(4):364-374.
15. Freeman A, Hamid S, Morris L, Vowler S, Rushbrook S, Wight DG, ColemanN, Alexander GJ: Improved detection of hepatocyte proliferation usingantibody to the pre-replication complex: an association with hepatic fibrosisand viral replication in chronic hepatitis C virus infection. J Viral Hepat2003,10(5):345-350.
16. Mantovani A: Cancer: Inflaming metastasis. Nature2009,457(7225):36-37.
17. Libbrecht L, Desmet V, Van Damme B, Roskams T: Deep intralobularextension of human hepatic 'progenitor cells' correlates with parenchymalinflammation in chronic viral hepatitis: can 'progenitor cells' migrate? J Pathol2000,192(3):373-378.
18. Kuang DM, Peng C, Zhao Q, Wu Y, Chen MS, Zheng L: Activated monocytesin peritumoral stroma of hepatocellular carcinoma promote expansion ofmemory T helper17cells. Hepatology2010,51(1):154-164.
19. Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, andcancer stem cells. Nature2001,414(6859):105-111.
20. Schmelzer E, Reid LM: EpCAM expression in normal, non-pathologicaltissues. Front Biosci2008,13:3096-3100.
21. Lu TY, Lu RM, Liao MY, Yu J, Chung CH, Kao CF, Wu HC: Epithelial celladhesion molecule regulation is associated with the maintenance of theundifferentiated phenotype of human embryonic stem cells. J Biol Chem2010,285(12):8719-8732.
22. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, Jia H, Ye Q, QinLX, Wauthier E et al: EpCAM-positive hepatocellular carcinoma cells aretumor-initiating cells with stem/progenitor cell features. Gastroenterology2009,136(3):1012-1024.
23. Murakata A, Tanaka S, Mogushi K, Yasen M, Noguchi N, Irie T, Kudo A,Nakamura N, Tanaka H, Arii S: Gene expression signature of the grossmorphology in hepatocellular carcinoma. Ann Surg2011,253(1):94-100.
24. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S,Sugawara Y, Minagawa M, Takayama T, Kawasaki S et al: Risk factorscontributing to early and late phase intrahepatic recurrence of hepatocellularcarcinoma after hepatectomy. J Hepatol2003,38(2):200-207.
25. Llovet JM: Updated treatment approach to hepatocellular carcinoma. JGastroenterol2005,40(3):225-235.
26. Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA,Giulini SM: Early and late recurrence after liver resection for hepatocellularcarcinoma: prognostic and therapeutic implications. Ann Surg2006,243(2):229-235.
27. Poon RT: Prevention of recurrence after resection of hepatocellular carcinoma:a daunting challenge. Hepatology2011,54(3):757-759.
28. Desmet VJ: Modulation of the liver in cholestasis. J Gastroenterol Hepatol1992,7(3):313-323.
29. Liu Z, Sakamoto T, Ezure T, Yokomuro S, Murase N, Michalopoulos G,Demetris AJ: Interleukin-6, hepatocyte growth factor, and their receptors inbiliary epithelial cells during a type I ductular reaction in mice: interactionsbetween the periductal inflammatory and stromal cells and the biliaryepithelium. Hepatology1998,28(5):1260-1268.
30. Roskams TA, Libbrecht L, Desmet VJ: Progenitor cells in diseased humanliver. Semin Liver Dis2003,23(4):385-396.
31. Bird TG, Lorenzini S, Forbes SJ: Activation of stem cells in hepatic diseases.Cell Tissue Res2008,331(1):283-300.
32. Lu XY, Xi T, Lau WY, Dong H, Zhu Z, Shen F, Wu MC, Cong WM:Hepatocellular Carcinoma Expressing Cholangiocyte Phenotype Is a NovelSubtype with Highly Aggressive Behavior. Ann Surg Oncol2011.
33. Li YW, Qiu SJ, Fan J, Zhou J, Gao Q, Xiao YS, Xu YF: Intratumoralneutrophils: a poor prognostic factor for hepatocellular carcinoma followingresection. J Hepatol2011,54(3):497-505.
34. Lopez PM, Villanueva A, Llovet JM: Systematic review: evidence-basedmanagement of hepatocellular carcinoma--an updated analysis of randomizedcontrolled trials. Aliment Pharmacol Ther2006,23(11):1535-1547.
35. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A,Gupta S, Moore J, Wrobel MJ, Lerner J et al: Gene expression in fixed tissuesand outcome in hepatocellular carcinoma. N Engl J Med2008,359(19):1995-2004.
36. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H,Desmet V, Korb G, MacSween RN et al: Histological grading and staging ofchronic hepatitis. J Hepatol1995,22(6):696-699.
37. Zhou H, Rogler LE, Teperman L, Morgan G, Rogler CE: Identification ofhepatocytic and bile ductular cell lineages and candidate stem cells in bipolarductular reactions in cirrhotic human liver. Hepatology2007,45(3):716-724.
38. Svegliati-Baroni G, Faraci G, Fabris L, Saccomanno S, Cadamuro M,Pierantonelli I, Trozzi L, Bugianesi E, Guido M, Strazzabosco M et al: Insulinresistance and necroinflammation drives ductular reaction andepithelial-mesenchymal transition in chronic hepatitis C. Gut2011,60(1):108-115.
39. Clouston AD, Powell EE, Walsh MJ, Richardson MM, Demetris AJ, JonssonJR: Fibrosis correlates with a ductular reaction in hepatitis C: roles of impairedreplication, progenitor cells and steatosis. Hepatology2005,41(4):809-818.
40. Richardson MM, Jonsson JR, Powell EE, Brunt EM, Neuschwander-Tetri BA,Bhathal PS, Dixon JB, Weltman MD, Tilg H, Moschen AR et al: Progressivefibrosis in nonalcoholic steatohepatitis: association with altered regenerationand a ductular reaction. Gastroenterology2007,133(1):80-90.
41. Fabris L, Cadamuro M, Guido M, Spirli C, Fiorotto R, Colledan M, Torre G,Alberti D, Sonzogni A, Okolicsanyi L et al: Analysis of liver repairmechanisms in Alagille syndrome and biliary atresia reveals a role for notchsignaling. Am J Pathol2007,171(2):641-653.
42. Tan J, Hytiroglou P, Wieczorek R, Park YN, Thung SN, Arias B, Theise ND:Immunohistochemical evidence for hepatic progenitor cells in liver diseases.Liver2002,22(5):365-373.
43. Napoli J, Bishop GA, McGuinness PH, Painter DM, McCaughan GW:Progressive liver injury in chronic hepatitis C infection correlates withincreased intrahepatic expression of Th1-associated cytokines. Hepatology1996,24(4):759-765.
44. Gochee PA, Jonsson JR, Clouston AD, Pandeya N, Purdie DM, Powell EE:Steatosis in chronic hepatitis C: association with increased messenger RNAexpression of collagen I, tumor necrosis factor-alpha and cytochrome P4502E1. J Gastroenterol Hepatol2003,18(4):386-392.
45. Fausto N: Liver regeneration and repair: hepatocytes, progenitor cells, andstem cells. Hepatology2004,39(6):1477-1487.
46. Kallis YN, Robson AJ, Fallowfield JA, Thomas HC, Alison MR, Wright NA,Goldin RD, Iredale JP, Forbes SJ: Remodelling of extracellular matrix is arequirement for the hepatic progenitor cell response. Gut2011,60(4):525-533.
47. Deng H, Wang HF, Gao YB, Jin XL, Xiao JC: Hepatic progenitor cellrepresents a transitioning cell population between liver epithelium and stroma.Med Hypotheses2011,76(6):809-812.
48. Pritchard MT, Nagy LE: Hepatic fibrosis is enhanced and accompanied byrobust oval cell activation after chronic carbon tetrachloride administration toEgr-1-deficient mice. Am J Pathol2010,176(6):2743-2752.
49. Clouston AD, Jonsson JR, Powell EE: Hepatic progenitor cell-mediatedregeneration and fibrosis: chicken or egg? Hepatology2009,49(5):1424-1426.
50. Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer.Cell2010,140(6):883-899.
51. Qian BZ, Pollard JW: Macrophage diversity enhances tumor progression andmetastasis. Cell2010,141(1):39-51.
52. White E, Karp C, Strohecker AM, Guo Y, Mathew R: Role of autophagy insuppression of inflammation and cancer. Curr Opin Cell Biol2010,22(2):212-217.
53. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell2011,144(5):646-674.
54. Larue L, Bellacosa A: Epithelial-mesenchymal transition in development andcancer: role of phosphatidylinositol3' kinase/AKT pathways. Oncogene2005,24(50):7443-7454.
55. Jing Y, Han Z, Liu Y, Sun K, Zhang S, Jiang G, Li R, Gao L, Zhao X, Wu Det al: Mesenchymal stem cells in inflammation microenvironment accelerateshepatocellular carcinoma metastasis by inducing epithelial-mesenchymaltransition. PLoS One2012,7(8):e43272.
56. Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, Wu WZ,Wang L, Tang ZY, Sun HC: High expression of macrophagecolony-stimulating factor in peritumoral liver tissue is associated with poorsurvival after curative resection of hepatocellular carcinoma. J Clin Oncol2008,26(16):2707-2716.
57. Sell S: Stem cell origin of cancer and differentiation therapy. Crit Rev OncolHematol2004,51(1):1-28.
58. Sell S, Pierce GB: Maturation arrest of stem cell differentiation is a commonpathway for the cellular origin of teratocarcinomas and epithelial cancers. LabInvest1994,70(1):6-22.
59. Sell S: Alpha-fetoprotein, stem cells and cancer: how study of the productionof alpha-fetoprotein during chemical hepatocarcinogenesis led to reaffirmationof the stem cell theory of cancer. Tumour Biol2008,29(3):161-180.
60. Libbrecht L: Hepatic progenitor cells in human liver tumor development.World J Gastroenterol2006,12(39):6261-6265.
61. Sell S, Leffert HL: Liver cancer stem cells. J Clin Oncol2008,26(17):2800-2805.
62. Ziol M, Nault JC, Aout M, Barget N, Tepper M, Martin A, Trinchet JC,Ganne-Carrie N, Vicaut E, Beaugrand M et al: Intermediate hepatobiliary cellspredict an increased risk of hepatocarcinogenesis in patients with hepatitis Cvirus-related cirrhosis. Gastroenterology2010,139(1):335-343e332.
63. Yang XR, Xu Y, Shi GM, Fan J, Zhou J, Ji Y, Sun HC, Qiu SJ, Yu B, Gao Qet al: Cytokeratin10and Cytokeratin19: Predictive Markers for PoorPrognosis in Hepatocellular Carcinoma Patients after Curative Resection.Clinical Cancer Research2008,14(12):3850-3859.
64. Zhuang PY, Zhang JB, Zhu XD, Zhang W, Wu WZ, Tan YS, Hou J, Tang ZY,Qin LX, Sun HC: Two pathologic types of hepatocellular carcinoma withlymph node metastasis with distinct prognosis on the basis of CK19expression in tumor. Cancer2008,112(12):2740-2748.
65. Uenishi T, Kubo S, Yamamoto T, Shuto T, Ogawa M, Tanaka H, Tanaka S,Kaneda K, Hirohashi K: Cytokeratin19expression in hepatocellularcarcinoma predicts early postoperative recurrence. Cancer Sci2003,94(10):851-857.
66. Tsuchiya K, Komuta M, Yasui Y, Tamaki N, Hosokawa T, Ueda K, Kuzuya T,Itakura J, Nakanishi H, Takahashi Y et al: Expression of keratin19is relatedto high recurrence of hepatocellular carcinoma after radiofrequency ablation.Oncology2011,80(3-4):278-288.
67. Lowes KN, Brennan BA, Yeoh GC, Olynyk JK: Oval cell numbers in humanchronic liver diseases are directly related to disease severity. Am J Pathol1999,154(2):537-541.
68. Roskams T, De Vos R, Van Eyken P, Myazaki H, Van Damme B, Desmet V:Hepatic OV-6expression in human liver disease and rat experiments: evidencefor hepatic progenitor cells in man. J Hepatol1998,29(3):455-463.
69. Kimura O, Takahashi T, Ishii N, Inoue Y, Ueno Y, Kogure T, Fukushima K,Shiina M, Yamagiwa Y, Kondo Y et al: Characterization of the epithelial celladhesion molecule (EpCAM)+cell population in hepatocellular carcinomacell lines. Cancer Sci2010,101(10):2145-2155.
70. Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, Budhu A, ZanettiKA, Chen Y, Qin LX et al: EpCAM and alpha-fetoprotein expression definesnovel prognostic subtypes of hepatocellular carcinoma. Cancer Res2008,68(5):1451-1461.
71. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, Jia H, Ye Q, QinLX, Wauthier E: EpCAM-Positive Hepatocellular Carcinoma Cells AreTumor-Initiating Cells With Stem/Progenitor Cell Features. Gastroenterology2009,136(3):1012-1024.e1014.
72. Cantz T, Manns MP, Ott M: Stem cells in liver regeneration and therapy. CellTissue Res2008,331(1):271-282.
73. Roskams T: Liver stem cells and their implication in hepatocellular andcholangiocarcinoma. Oncogene2006,25(27):3818-3822.
74. Roskams T: Progenitor cell involvement in cirrhotic human liver diseases:from controversy to consensus. J Hepatol2003,39(3):431-434.
1. El-Serag HB: Hepatocellular carcinoma. N Engl J Med2011,365(12):1118-1127.
2. Ramakrishna G, Rastogi A, Trehanpati N, Sen B, Khosla R, Sarin SK: FromCirrhosis to Hepatocellular Carcinoma: New Molecular Insights onInflammation and Cellular Senescence. Liver Cancer2013,2(3-4):367-383.
3. Douarin NM: An experimental analysis of liver development. Med Biol1975,53(6):427-455.
4. Gualdi R, Bossard P, Zheng M, Hamada Y, Coleman JR, Zaret KS: Hepaticspecification of the gut endoderm in vitro: cell signaling and transcriptionalcontrol. Genes Dev1996,10(13):1670-1682.
5. Jung J, Zheng M, Goldfarb M, Zaret KS: Initiation of mammalian liverdevelopment from endoderm by fibroblast growth factors. Science1999,284(5422):1998-2003.
6. Rossi JM, Dunn NR, Hogan BL, Zaret KS: Distinct mesodermal signals,including BMPs from the septum transversum mesenchyme, are required incombination for hepatogenesis from the endoderm. Genes Dev2001,15(15):1998-2009.
7. Ober EA, Verkade H, Field HA, Stainier DY: Mesodermal Wnt2b signallingpositively regulates liver specification. Nature2006,442(7103):688-691.
8. Sosa-Pineda B, Wigle JT, Oliver G: Hepatocyte migration during liverdevelopment requires Prox1. Nat Genet2000,25(3):254-255.
9. Zaret K: Early liver differentiation: genetic potentiation and multilevel growthcontrol. Curr Opin Genet Dev1998,8(5):526-531.
10. Matsumoto K, Yoshitomi H, Rossant J, Zaret KS: Liver organogenesispromoted by endothelial cells prior to vascular function. Science2001,294(5542):559-563.
11. Kubota H, Reid LM: Clonogenic hepatoblasts, common precursors forhepatocytic and biliary lineages, are lacking classical major histocompatibilitycomplex class I antigen. Proc Natl Acad Sci U S A2000,97(22):12132-12137.
12. Suzuki A, Zheng Y, Kondo R, Kusakabe M, Takada Y, Fukao K, Nakauchi H,Taniguchi H: Flow-cytometric separation and enrichment of hepatic progenitorcells in the developing mouse liver. Hepatology2000,32(6):1230-1239.
13. Minguet S, Cortegano I, Gonzalo P, Martinez-Marin JA, de Andres B, Salas C,Melero D, Gaspar ML, Marcos MA: A population ofc-Kit(low)(CD45/TER119)-hepatic cell progenitors of11-day postcoitusmouse embryo liver reconstitutes cell-depleted liver organoids. J Clin Invest2003,112(8):1152-1163.
14. Tanimizu N, Nishikawa M, Saito H, Tsujimura T, Miyajima A: Isolation ofhepatoblasts based on the expression of Dlk/Pref-1. J Cell Sci2003,116(Pt9):1775-1786.
15. Floridon C, Jensen CH, Thorsen P, Nielsen O, Sunde L, Westergaard JG,Thomsen SG, Teisner B: Does fetal antigen1(FA1) identify cells withregenerative, endocrine and neuroendocrine potentials? A study of FA1inembryonic, fetal, and placental tissue and in maternal circulation.Differentiation2000,66(1):49-59.
16. Yanai H, Nakamura K, Hijioka S, Kamei A, Ikari T, Ishikawa Y, Shinozaki E,Mizunuma N, Hatake K, Miyajima A: Dlk-1, a cell surface antigen on foetalhepatic stem/progenitor cells, is expressed in hepatocellular, colon, pancreasand breast carcinomas at a high frequency. J Biochem2010,148(1):85-92.
17. Nierhoff D, Ogawa A, Oertel M, Chen YQ, Shafritz DA: Purification andcharacterization of mouse fetal liver epithelial cells with high in vivorepopulation capacity. Hepatology2005,42(1):130-139.
18. Tanaka M, Okabe M, Suzuki K, Kamiya Y, Tsukahara Y, Saito S, Miyajima A:Mouse hepatoblasts at distinct developmental stages are characterized byexpression of EpCAM and DLK1: drastic change of EpCAM expressionduring liver development. Mech Dev2009,126(8-9):665-676.
19. Dan YY, Riehle KJ, Lazaro C, Teoh N, Haque J, Campbell JS, Fausto N:Isolation of multipotent progenitor cells from human fetal liver capable ofdifferentiating into liver and mesenchymal lineages. Proc Natl Acad Sci U S A2006,103(26):9912-9917.
20. Schmelzer E, Zhang L, Bruce A, Wauthier E, Ludlow J, Yao HL, Moss N,Melhem A, McClelland R, Turner W et al: Human hepatic stem cells fromfetal and postnatal donors. J Exp Med2007,204(8):1973-1987.
21. Kakinuma S, Ohta H, Kamiya A, Yamazaki Y, Oikawa T, Okada K, NakauchiH: Analyses of cell surface molecules on hepatic stem/progenitor cells inmouse fetal liver. J Hepatol2009,51(1):127-138.
22. Antoniou A, Raynaud P, Cordi S, Zong Y, Tronche F, Stanger BZ, Jacquemin P,Pierreux CE, Clotman F, Lemaigre FP: Intrahepatic bile ducts developaccording to a new mode of tubulogenesis regulated by the transcription factorSOX9. Gastroenterology2009,136(7):2325-2333.
23. Clotman F, Jacquemin P, Plumb-Rudewiez N, Pierreux CE, Van der Smissen P,Dietz HC, Courtoy PJ, Rousseau GG, Lemaigre FP: Control of liver cell fatedecision by a gradient of TGF beta signaling modulated by Onecuttranscription factors. Genes Dev2005,19(16):1849-1854.
24. Suzuki K, Tanaka M, Watanabe N, Saito S, Nonaka H, Miyajima A: p75Neurotrophin receptor is a marker for precursors of stellate cells and portalfibroblasts in mouse fetal liver. Gastroenterology2008,135(1):270-281e273.
25. Tanimizu N, Miyajima A: Notch signaling controls hepatoblast differentiationby altering the expression of liver-enriched transcription factors. J Cell Sci2004,117(Pt15):3165-3174.
26. Zong Y, Panikkar A, Xu J, Antoniou A, Raynaud P, Lemaigre F, Stanger BZ:Notch signaling controls liver development by regulating biliarydifferentiation. Development2009,136(10):1727-1739.
27. Tanaka M, Itoh T, Tanimizu N, Miyajima A: Liver stem/progenitor cells: theircharacteristics and regulatory mechanisms. J Biochem2011,149(3):231-239.
28. Geisler F, Nagl F, Mazur PK, Lee M, Zimber-Strobl U, Strobl LJ, Radtke F,Schmid RM, Siveke JT: Liver-specific inactivation of Notch2, but not Notch1,compromises intrahepatic bile duct development in mice. Hepatology2008,48(2):607-616.
29. Lozier J, McCright B, Gridley T: Notch signaling regulates bile ductmorphogenesis in mice. PLoS One2008,3(3):e1851.
30. Sparks EE, Huppert KA, Brown MA, Washington MK, Huppert SS: Notchsignaling regulates formation of the three-dimensional architecture ofintrahepatic bile ducts in mice. Hepatology2010,51(4):1391-1400.
31. Tchorz JS, Kinter J, Muller M, Tornillo L, Heim MH, Bettler B: Notch2signaling promotes biliary epithelial cell fate specification and tubulogenesisduring bile duct development in mice. Hepatology2009,50(3):871-879.
32. Clotman F, Lannoy VJ, Reber M, Cereghini S, Cassiman D, Jacquemin P,Roskams T, Rousseau GG, Lemaigre FP: The onecut transcription factorHNF6is required for normal development of the biliary tract. Development2002,129(8):1819-1828.
33. Coffinier C, Gresh L, Fiette L, Tronche F, Schutz G, Babinet C, Pontoglio M,Yaniv M, Barra J: Bile system morphogenesis defects and liver dysfunctionupon targeted deletion of HNF1beta. Development2002,129(8):1829-1838.
34. Hunter MP, Wilson CM, Jiang X, Cong R, Vasavada H, Kaestner KH, BogueCW: The homeobox gene Hhex is essential for proper hepatoblastdifferentiation and bile duct morphogenesis. Dev Biol2007,308(2):355-367.
35. Kodama Y, Hijikata M, Kageyama R, Shimotohno K, Chiba T: The role ofnotch signaling in the development of intrahepatic bile ducts.Gastroenterology2004,127(6):1775-1786.
36. Krupczak-Hollis K, Wang X, Kalinichenko VV, Gusarova GA, Wang IC,Dennewitz MB, Yoder HM, Kiyokawa H, Kaestner KH, Costa RH: The mouseForkhead Box m1transcription factor is essential for hepatoblast mitosis anddevelopment of intrahepatic bile ducts and vessels during liver morphogenesis.Dev Biol2004,276(1):74-88.
37. Li Z, White P, Tuteja G, Rubins N, Sackett S, Kaestner KH: Foxa1and Foxa2regulate bile duct development in mice. J Clin Invest2009,119(6):1537-1545.
38. Oikawa T, Kamiya A, Kakinuma S, Zeniya M, Nishinakamura R, Tajiri H,Nakauchi H: Sall4regulates cell fate decision in fetal hepatic stem/progenitorcells. Gastroenterology2009,136(3):1000-1011.
39. Suzuki A, Sekiya S, Buscher D, Izpisua Belmonte JC, Taniguchi H: Tbx3controls the fate of hepatic progenitor cells in liver development bysuppressing p19ARF expression. Development2008,135(9):1589-1595.
40. Raynaud P, Carpentier R, Antoniou A, Lemaigre FP: Biliary differentiationand bile duct morphogenesis in development and disease. Int J Biochem CellBiol2011,43(2):245-256.
41. Tanimizu N, Miyajima A, Mostov KE: Liver progenitor cells developcholangiocyte-type epithelial polarity in three-dimensional culture. Mol BiolCell2007,18(4):1472-1479.
42. Tanimizu N, Miyajima A, Mostov KE: Liver progenitor cells fold up a cellmonolayer into a double-layered structure during tubular morphogenesis. MolBiol Cell2009,20(9):2486-2494.
43. Tanimizu N, Saito H, Mostov K, Miyajima A: Long-term culture of hepaticprogenitors derived from mouse Dlk+hepatoblasts. J Cell Sci2004,117(Pt26):6425-6434.
44. Strick-Marchand H, Morosan S, Charneau P, Kremsdorf D, Weiss MC:Bipotential mouse embryonic liver stem cell lines contribute to liverregeneration and differentiate as bile ducts and hepatocytes. Proc Natl AcadSci U S A2004,101(22):8360-8365.
45. Asahina K, Tsai SY, Li P, Ishii M, Maxson RE, Jr., Sucov HM, Tsukamoto H:Mesenchymal origin of hepatic stellate cells, submesothelial cells, andperivascular mesenchymal cells during mouse liver development. Hepatology2009,49(3):998-1011.
46. Onitsuka I, Tanaka M, Miyajima A: Characterization and functional analysesof hepatic mesothelial cells in mouse liver development. Gastroenterology2010,138(4):1525-1535,1535e1521-1526.
47. Ijpenberg A, Perez-Pomares JM, Guadix JA, Carmona R, Portillo-Sanchez V,Macias D, Hohenstein P, Miles CM, Hastie ND, Munoz-Chapuli R: Wt1andretinoic acid signaling are essential for stellate cell development and livermorphogenesis. Dev Biol2007,312(1):157-170.
48. Kamiya A, Kinoshita T, Ito Y, Matsui T, Morikawa Y, Senba E, Nakashima K,Taga T, Yoshida K, Kishimoto T et al: Fetal liver development requires aparacrine action of oncostatin M through the gp130signal transducer. EMBO J1999,18(8):2127-2136.
49. Kinoshita T, Sekiguchi T, Xu MJ, Ito Y, Kamiya A, Tsuji K, Nakahata T,Miyajima A: Hepatic differentiation induced by oncostatin M attenuates fetalliver hematopoiesis. Proc Natl Acad Sci U S A1999,96(13):7265-7270.
50. Michalopoulos GK: Liver regeneration after partial hepatectomy: criticalanalysis of mechanistic dilemmas. Am J Pathol2010,176(1):2-13.
51. Overturf K, al-Dhalimy M, Ou CN, Finegold M, Grompe M: Serialtransplantation reveals the stem-cell-like regenerative potential of adult mousehepatocytes. Am J Pathol1997,151(5):1273-1280.
52. Alison MR, Golding MH, Sarraf CE: Pluripotential liver stem cells: facultativestem cells located in the biliary tree. Cell Prolif1996,29(7):373-402.
53. Roskams TA, Theise ND, Balabaud C, Bhagat G, Bhathal PS, Bioulac-Sage P,Brunt EM, Crawford JM, Crosby HA, Desmet V et al: Nomenclature of thefiner branches of the biliary tree: canals, ductules, and ductular reactions inhuman livers. Hepatology2004,39(6):1739-1745.
54. Theise ND, Saxena R, Portmann BC, Thung SN, Yee H, Chiriboga L, KumarA, Crawford JM: The canals of Hering and hepatic stem cells in humans.Hepatology1999,30(6):1425-1433.
55. Farber E: Similarities in the sequence of early histological changes induced inthe liver of the rat by ethionine,2-acetylamino-fluorene, and3'-methyl-4-dimethylaminoazobenzene. Cancer Res1956,16(2):142-148.
56. Paku S, Schnur J, Nagy P, Thorgeirsson SS: Origin and structural evolution ofthe early proliferating oval cells in rat liver. Am J Pathol2001,158(4):1313-1323.
57. Petersen BE, Bowen WC, Patrene KD, Mars WM, Sullivan AK, Murase N,Boggs SS, Greenberger JS, Goff JP: Bone marrow as a potential source ofhepatic oval cells. Science1999,284(5417):1168-1170.
58. Fausto N: Liver regeneration and repair: hepatocytes, progenitor cells, andstem cells. Hepatology2004,39(6):1477-1487.
59. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, Mikaelyan A,Roberts LR, Demetris AJ, Sun Z et al: A novel prognostic subtype of humanhepatocellular carcinoma derived from hepatic progenitor cells. Nat Med2006,12(4):410-416.
60. Evarts RP, Nagy P, Marsden E, Thorgeirsson SS: A precursor-productrelationship exists between oval cells and hepatocytes in rat liver.Carcinogenesis1987,8(11):1737-1740.
61. Laishes BA, Rolfe PB: Search for endogenous liver colony-forming units inF344rats given a two-thirds hepatectomy during short-term feeding of2-acetylaminofluorene. Cancer Res1981,41(5):1731-1741.
62. Akhurst B, Croager EJ, Farley-Roche CA, Ong JK, Dumble ML, Knight B,Yeoh GC: A modified choline-deficient, ethionine-supplemented diet protocoleffectively induces oval cells in mouse liver. Hepatology2001,34(3):519-522.
63. Preisegger KH, Factor VM, Fuchsbichler A, Stumptner C, Denk H,Thorgeirsson SS: Atypical ductular proliferation and its inhibition bytransforming growth factor beta1in the3,5-diethoxycarbonyl-1,4-dihydrocollidine mouse model for chronic alcoholicliver disease. Lab Invest1999,79(2):103-109.
64. Wang X, Foster M, Al-Dhalimy M, Lagasse E, Finegold M, Grompe M: Theorigin and liver repopulating capacity of murine oval cells. Proc Natl Acad SciU S A2003,100Suppl1:11881-11888.
65. Yovchev MI, Grozdanov PN, Joseph B, Gupta S, Dabeva MD: Novel hepaticprogenitor cell surface markers in the adult rat liver. Hepatology2007,45(1):139-149.
66. Yovchev MI, Grozdanov PN, Zhou H, Racherla H, Guha C, Dabeva MD:Identification of adult hepatic progenitor cells capable of repopulating injuredrat liver. Hepatology2008,47(2):636-647.
67. Suzuki A, Sekiya S, Onishi M, Oshima N, Kiyonari H, Nakauchi H, TaniguchiH: Flow cytometric isolation and clonal identification of self-renewingbipotent hepatic progenitor cells in adult mouse liver. Hepatology2008,48(6):1964-1978.
68. Okabe M, Tsukahara Y, Tanaka M, Suzuki K, Saito S, Kamiya Y, Tsujimura T,Nakamura K, Miyajima A: Potential hepatic stem cells reside in EpCAM+cells of normal and injured mouse liver. Development2009,136(11):1951-1960.
69. Fougere-Deschatrette C, Imaizumi-Scherrer T, Strick-Marchand H, Morosan S,Charneau P, Kremsdorf D, Faust DM, Weiss MC: Plasticity of hepatic celldifferentiation: bipotential adult mouse liver clonal cell lines competent todifferentiate in vitro and in vivo. Stem Cells2006,24(9):2098-2109.
70. Kamiya A, Kakinuma S, Yamazaki Y, Nakauchi H: Enrichment and clonalculture of progenitor cells during mouse postnatal liver development in mice.Gastroenterology2009,137(3):1114-1126,1126e1111-1114.
71. Knight B, Akhurst B, Matthews VB, Ruddell RG, Ramm GA, Abraham LJ,Olynyk JK, Yeoh GC: Attenuated liver progenitor (oval) cell and fibrogenicresponses to the choline deficient, ethionine supplemented diet in the BALB/cinbred strain of mice. J Hepatol2007,46(1):134-141.
72. Strick-Marchand H, Masse GX, Weiss MC, Di Santo JP: Lymphocytes supportoval cell-dependent liver regeneration. J Immunol2008,181(4):2764-2771.
73. Akhurst B, Matthews V, Husk K, Smyth MJ, Abraham LJ, Yeoh GC:Differential lymphotoxin-beta and interferon gamma signaling during mouseliver regeneration induced by chronic and acute injury. Hepatology2005,41(2):327-335.
74. Knight B, Yeoh GC, Husk KL, Ly T, Abraham LJ, Yu C, Rhim JA, Fausto N:Impaired preneoplastic changes and liver tumor formation in tumor necrosisfactor receptor type1knockout mice. J Exp Med2000,192(12):1809-1818.
75. Jakubowski A, Ambrose C, Parr M, Lincecum JM, Wang MZ, Zheng TS,Browning B, Michaelson JS, Baetscher M, Wang B et al: TWEAK inducesliver progenitor cell proliferation. J Clin Invest2005,115(9):2330-2340.
76. Tirnitz-Parker JE, Viebahn CS, Jakubowski A, Klopcic BR, Olynyk JK, YeohGC, Knight B: Tumor necrosis factor-like weak inducer of apoptosis is amitogen for liver progenitor cells. Hepatology2010,52(1):291-302.
77. Yovchev MI, Zhang J, Neufeld DS, Grozdanov PN, Dabeva MD: Thymus cellantigen-1-expressing cells in the oval cell compartment. Hepatology2009,50(2):601-611.
78. Apte U, Thompson MD, Cui S, Liu B, Cieply B, Monga SP: Wnt/beta-cateninsignaling mediates oval cell response in rodents. Hepatology2008,47(1):288-295.
79. Hu M, Kurobe M, Jeong YJ, Fuerer C, Ghole S, Nusse R, Sylvester KG:Wnt/beta-catenin signaling in murine hepatic transit amplifying progenitorcells. Gastroenterology2007,133(5):1579-1591.
80. Itoh T, Kamiya Y, Okabe M, Tanaka M, Miyajima A: Inducible expression ofWnt genes during adult hepatic stem/progenitor cell response. FEBS Lett2009,583(4):777-781.
81. Yang W, Yan HX, Chen L, Liu Q, He YQ, Yu LX, Zhang SH, Huang DD, TangL, Kong XN et al: Wnt/beta-catenin signaling contributes to activation ofnormal and tumorigenic liver progenitor cells. Cancer Res2008,68(11):4287-4295.
82. Yang XR, Xu Y, Yu B, Zhou J, Qiu SJ, Shi GM, Zhang BH, Wu WZ, Shi YH,Wu B et al: High expression levels of putative hepatic stem/progenitor cellbiomarkers related to tumour angiogenesis and poor prognosis ofhepatocellular carcinoma. Gut2010,59(7):953-962.
83. Yeh CT, Kuo CJ, Lai MW, Chen TC, Lin CY, Yeh TS, Lee WC:CD133-positive hepatocellular carcinoma in an area endemic for hepatitis Bvirus infection. BMC Cancer2009,9:324.
84. Kim H, Choi GH, Na DC, Ahn EY, Kim GI, Lee JE, Cho JY, Yoo JE, Choi JS,Park YN: Human hepatocellular carcinomas with "Stemness"-related markerexpression: keratin19expression and a poor prognosis. Hepatology2011,54(5):1707-1717.
85. Wu PC, Fang JW, Lau VK, Lai CL, Lo CK, Lau JY: Classification ofhepatocellular carcinoma according to hepatocellular and biliarydifferentiation markers. Clinical and biological implications. Am J Pathol1996,149(4):1167-1175.
86. Durnez A, Verslype C, Nevens F, Fevery J, Aerts R, Pirenne J, Lesaffre E,Libbrecht L, Desmet V, Roskams T: The clinicopathological and prognosticrelevance of cytokeratin7and19expression in hepatocellular carcinoma. Apossible progenitor cell origin. Histopathology2006,49(2):138-151.
87. Woo HG, Lee JH, Yoon JH, Kim CY, Lee HS, Jang JJ, Yi NJ, Suh KS, Lee KU,Park ES et al: Identification of a cholangiocarcinoma-like gene expression traitin hepatocellular carcinoma. Cancer Res2010,70(8):3034-3041.
88. Cai X, Zhai J, Kaplan DE, Zhang Y, Zhou L, Chen X, Qian G, Zhao Q, Li Y,Gao L et al: Background progenitor activation is associated with recurrenceafter hepatectomy of combined hepatocellular-cholangiocarcinoma.Hepatology2012,56(5):1804-1816.
89. Tsuchiya A, Kamimura H, Tamura Y, Takamura M, Yamagiwa S, Suda T,Nomoto M, Aoyagi Y: Hepatocellular carcinoma with progenitor cell featuresdistinguishable by the hepatic stem/progenitor cell marker NCAM. CancerLett2011,309(1):95-103.
90. Oliva J, French BA, Qing X, French SW: The identification of stem cells inhuman liver diseases and hepatocellular carcinoma. Exp Mol Pathol2010,88(3):331-340.
91. Ziol M, Nault JC, Aout M, Barget N, Tepper M, Martin A, Trinchet JC,Ganne-Carrie N, Vicaut E, Beaugrand M et al: Intermediate hepatobiliary cellspredict an increased risk of hepatocarcinogenesis in patients with hepatitis Cvirus-related cirrhosis. Gastroenterology2010,139(1):335-343e332.
92. Lee TK, Castilho A, Ma S, Ng IO: Liver cancer stem cells: implications for anew therapeutic target. Liver Int2009,29(7):955-965.
93. Chiba T, Kamiya A, Yokosuka O, Iwama A: Cancer stem cells inhepatocellular carcinoma: Recent progress and perspective. Cancer Lett2009,286(2):145-153.
94. Lee TK, Cheung VC, Ng IO: Liver tumor-initiating cells as a therapeutictarget for hepatocellular carcinoma. Cancer Lett2013,338(1):101-109.
95. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell2011,144(5):646-674.
96. Mueller K: Inflammation. Inflammation's yin-yang. Introduction. Science2013,339(6116):155.
97. Crispe IN: The liver as a lymphoid organ. Annu Rev Immunol2009,27:147-163.
98. Liaskou E, Wilson DV, Oo YH: Innate immune cells in liver inflammation.Mediators Inflamm2012,2012:949157.
99. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S,Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y: NF-kappaBfunctions as a tumour promoter in inflammation-associated cancer. Nature2004,431(7007):461-466.
100. Haybaeck J, Zeller N, Wolf MJ, Weber A, Wagner U, Kurrer MO, Bremer J,Iezzi G, Graf R, Clavien PA et al: A lymphotoxin-driven pathway tohepatocellular carcinoma. Cancer Cell2009,16(4):295-308.
101. Liu P, Kimmoun E, Legrand A, Sauvanet A, Degott C, Lardeux B, Bernuau D:Activation of NF-kappa B, AP-1and STAT transcription factors is a frequentand early event in human hepatocellular carcinomas. J Hepatol2002,37(1):63-71.
102. Luedde T, Schwabe RF: NF-kappaB in the liver--linking injury, fibrosis andhepatocellular carcinoma. Nat Rev Gastroenterol Hepatol2011,8(2):108-118.
103. He G, Yu GY, Temkin V, Ogata H, Kuntzen C, Sakurai T, Sieghart W,Peck-Radosavljevic M, Leffert HL, Karin M: Hepatocyte IKKbeta/NF-kappaBinhibits tumor promotion and progression by preventing oxidativestress-driven STAT3activation. Cancer Cell2010,17(3):286-297.
104. He G, Karin M: NF-kappaB and STAT3-key players in liver inflammationand cancer. Cell Res2011,21(1):159-168.
105. Das M, Sabio G, Jiang F, Rincon M, Flavell RA, Davis RJ: Induction ofhepatitis by JNK-mediated expression of TNF-alpha. Cell2009,136(2):249-260.
106. Das M, Garlick DS, Greiner DL, Davis RJ: The role of JNK in thedevelopment of hepatocellular carcinoma. Genes Dev2011,25(6):634-645.
107. Han MS, Jung DY, Morel C, Lakhani SA, Kim JK, Flavell RA, Davis RJ: JNKexpression by macrophages promotes obesity-induced insulin resistance andinflammation. Science2013,339(6116):218-222.
108. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M:Gender disparity in liver cancer due to sex differences in MyD88-dependentIL-6production. Science2007,317(5834):121-124.
109. Prieto J: Inflammation, HCC and sex: IL-6in the centre of the triangle. JHepatol2008,48(2):380-381.
110. Yang X, Schadt EE, Wang S, Wang H, Arnold AP, Ingram-Drake L, Drake TA,Lusis AJ: Tissue-specific expression and regulation of sexually dimorphicgenes in mice. Genome Res2006,16(8):995-1004.
111. Waxman DJ, Celenza JL: Sexual dimorphism of hepatic gene expression:novel biological role of KRAB zinc finger repressors revealed. Genes Dev2003,17(21):2607-2613.
112. Pinheiro I, Dejager L, Libert C: X-chromosome-located microRNAs inimmunity: might they explain male/female differences? The Xchromosome-genomic context may affect X-located miRNAs and downstreamsignaling, thereby contributing to the enhanced immune response of females.Bioessays2011,33(11):791-802.
113. Ingersoll MA, Platt AM, Potteaux S, Randolph GJ: Monocyte trafficking inacute and chronic inflammation. Trends Immunol2011,32(10):470-477.
114. Tacke F: Functional role of intrahepatic monocyte subsets for the progressionof liver inflammation and liver fibrosis in vivo. Fibrogenesis Tissue Repair2012,5Suppl1:S27.
115. Zimmermann HW, Seidler S, Nattermann J, Gassler N, Hellerbrand C,Zernecke A, Tischendorf JJ, Luedde T, Weiskirchen R, Trautwein C et al:Functional contribution of elevated circulating and hepatic non-classicalCD14CD16monocytes to inflammation and human liver fibrosis. PLoS One2010,5(6):e11049.
116. Karlmark KR, Weiskirchen R, Zimmermann HW, Gassler N, Ginhoux F,Weber C, Merad M, Luedde T, Trautwein C, Tacke F: Hepatic recruitment ofthe inflammatory Gr1+monocyte subset upon liver injury promotes hepaticfibrosis. Hepatology2009,50(1):261-274.
117. Deleve LD, Wang X, Guo Y: Sinusoidal endothelial cells prevent rat stellatecell activation and promote reversion to quiescence. Hepatology2008,48(3):920-930.
118. Connolly MK, Bedrosian AS, Malhotra A, Henning JR, Ibrahim J, Vera V,Cieza-Rubio NE, Hassan BU, Pachter HL, Cohen S et al: In hepatic fibrosis,liver sinusoidal endothelial cells acquire enhanced immunogenicity. JImmunol2010,185(4):2200-2208.
119. Brusko TM, Putnam AL, Bluestone JA: Human regulatory T cells: role inautoimmune disease and therapeutic opportunities. Immunol Rev2008,223:371-390.
120. Sasaki M, Ikeda H, Sawada S, Sato Y, Nakanuma Y: Naturally-occurringregulatory T cells are increased in inflamed portal tracts with cholangiopathyin primary biliary cirrhosis. J Clin Pathol2007,60(10):1102-1107.
121. Trehanpati N, Shrivastav S, Shivakumar B, Khosla R, Bhardwaj S, ChaturvediJ, Sukriti, Kumar B, Bose S, Mani Tripathi D et al: Analysis of Notch andTGF-beta Signaling Expression in Different Stages of Disease ProgressionDuring Hepatitis B Virus Infection. Clin Transl Gastroenterol2012,3:e23.
122. Martinon F, Mayor A, Tschopp J: The inflammasomes: guardians of the body.Annu Rev Immunol2009,27:229-265.
123. Schroder K, Tschopp J: The inflammasomes. Cell2010,140(6):821-832.
124. Davis BK, Wen H, Ting JP: The inflammasome NLRs in immunity,inflammation, and associated diseases. Annu Rev Immunol2011,29:707-735.
125. Boaru SG, Borkham-Kamphorst E, Tihaa L, Haas U, Weiskirchen R:Expression analysis of inflammasomes in experimental models ofinflammatory and fibrotic liver disease. J Inflamm (Lond)2012,9(1):49.
126. Szabo G, Csak T: Inflammasomes in liver diseases. J Hepatol2012,57(3):642-654.
127. Imaeda AB, Watanabe A, Sohail MA, Mahmood S, Mohamadnejad M,Sutterwala FS, Flavell RA, Mehal WZ: Acetaminophen-inducedhepatotoxicity in mice is dependent on Tlr9and the Nalp3inflammasome. JClin Invest2009,119(2):305-314.
128. Ganz M, Csak T, Nath B, Szabo G: Lipopolysaccharide induces and activatesthe Nalp3inflammasome in the liver. World J Gastroenterol2011,17(43):4772-4778.
129. Burdette D, Haskett A, Presser L, McRae S, Iqbal J, Waris G: Hepatitis C virusactivates interleukin-1beta via caspase-1-inflammasome complex. J Gen Virol2012,93(Pt2):235-246.
130. Petrasek J, Bala S, Csak T, Lippai D, Kodys K, Menashy V, Barrieau M, MinSY, Kurt-Jones EA, Szabo G: IL-1receptor antagonist amelioratesinflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest2012,122(10):3476-3489.
131. Svegliati-Baroni G, Faraci G, Fabris L, Saccomanno S, Cadamuro M,Pierantonelli I, Trozzi L, Bugianesi E, Guido M, Strazzabosco M et al: Insulinresistance and necroinflammation drives ductular reaction andepithelial-mesenchymal transition in chronic hepatitis C. Gut2011,60(1):108-115.
132. Falkowski O, An HJ, Ianus IA, Chiriboga L, Yee H, West AB, Theise ND:Regeneration of hepatocyte 'buds' in cirrhosis from intrabiliary stem cells. JHepatol2003,39(3):357-364.
133. Fausto N, Campbell JS, Riehle KJ: Liver regeneration. J Hepatol2012,57(3):692-694.
134. Gouw AS, Clouston AD, Theise ND: Ductular reactions in human liver:diversity at the interface. Hepatology2011,54(5):1853-1863.
135. Zhou H, Rogler LE, Teperman L, Morgan G, Rogler CE: Identification ofhepatocytic and bile ductular cell lineages and candidate stem cells in bipolarductular reactions in cirrhotic human liver. Hepatology2007,45(3):716-724.
136. Hanna RF, Aguirre DA, Kased N, Emery SC, Peterson MR, Sirlin CB:Cirrhosis-associated hepatocellular nodules: correlation of histopathologic andMR imaging features. Radiographics2008,28(3):747-769.
137. Lin WR, Lim SN, McDonald SA, Graham T, Wright VL, Peplow CL,Humphries A, Kocher HM, Wright NA, Dhillon AP et al: The histogenesis ofregenerative nodules in human liver cirrhosis. Hepatology2010,51(3):1017-1026.
138. Wright TL: Regenerating nodules--are they premalignant lesions? Hepatology1991,13(6):1254-1255.
139. Ng CH, Chan SW, Lee WK, Lai L, Lok KH, Li KK, Luk SH, Szeto ML:Hepatocarcinogenesis of regenerative and dysplastic nodules in Chinesepatients. Hong Kong Med J2011,17(1):11-19.
140. Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM: Role of themicroenvironment in the pathogenesis and treatment of hepatocellularcarcinoma. Gastroenterology2013,144(3):512-527.
141. Seitz HK, Stickel F: Risk factors and mechanisms of hepatocarcinogenesiswith special emphasis on alcohol and oxidative stress. Biol Chem2006,387(4):349-360.
142. Missiha SB, Ostrowski M, Heathcote EJ: Disease progression in chronichepatitis C: modifiable and nonmodifiable factors. Gastroenterology2008,134(6):1699-1714.
143. Bataller R, North KE, Brenner DA: Genetic polymorphisms and theprogression of liver fibrosis: a critical appraisal. Hepatology2003,37(3):493-503.
144. Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH,Shorthouse C, Purdie DM, Jonsson JR: Host genetic factors influence diseaseprogression in chronic hepatitis C. Hepatology2000,31(4):828-833.
145. Huang H, Shiffman ML, Friedman S, Venkatesh R, Bzowej N, Abar OT,Rowland CM, Catanese JJ, Leong DU, Sninsky JJ et al: A7gene signatureidentifies the risk of developing cirrhosis in patients with chronic hepatitis C.Hepatology2007,46(2):297-306.
146. Marcolongo M, Young B, Dal Pero F, Fattovich G, Peraro L, Guido M,Sebastiani G, Palu G, Alberti A: A seven-gene signature (cirrhosis risk score)predicts liver fibrosis progression in patients with initially mild chronichepatitis C. Hepatology2009,50(4):1038-1044.
147. Minouchi K, Kaneko S, Kobayashi K: Mutation of p53gene in regenerativenodules in cirrhotic liver. J Hepatol2002,37(2):231-239.
148. Calado RT, Brudno J, Mehta P, Kovacs JJ, Wu C, Zago MA, Chanock SJ,Boyer TD, Young NS: Constitutional telomerase mutations are genetic riskfactors for cirrhosis. Hepatology2011,53(5):1600-1607.
149. Hartmann D, Srivastava U, Thaler M, Kleinhans KN, N'Kontchou G,Scheffold A, Bauer K, Kratzer RF, Kloos N, Katz SF et al: Telomerase genemutations are associated with cirrhosis formation. Hepatology2011,53(5):1608-1617.
150. Di Gioia S, Bianchi P, Destro A, Grizzi F, Malesci A, Laghi L, Levrero M,Morabito A, Roncalli M: Quantitative evaluation of RASSF1A methylation inthe non-lesional, regenerative and neoplastic liver. BMC Cancer2006,6:89.
151. Um TH, Kim H, Oh BK, Kim MS, Kim KS, Jung G, Park YN: Aberrant CpGisland hypermethylation in dysplastic nodules and early HCC of hepatitis Bvirus-related human multistep hepatocarcinogenesis. J Hepatol2011,54(5):939-947.
152. Shay JW, Wright WE: Hayflick, his limit, and cellular ageing. Nat Rev MolCell Biol2000,1(1):72-76.
153. Yaswen P, Campisi J: Oncogene-induced senescence pathways weave anintricate tapestry. Cell2007,128(2):233-234.
154. Adams PD: Healing and hurting: molecular mechanisms, functions, andpathologies of cellular senescence. Mol Cell2009,36(1):2-14.
155. Krizhanovsky V, Yon M, Dickins RA, Hearn S, Simon J, Miething C, Yee H,Zender L, Lowe SW: Senescence of activated stellate cells limits liver fibrosis.Cell2008,134(4):657-667.
156. Schnabl B, Purbeck CA, Choi YH, Hagedorn CH, Brenner D: Replicativesenescence of activated human hepatic stellate cells is accompanied by apronounced inflammatory but less fibrogenic phenotype. Hepatology2003,37(3):653-664.
157. Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, HohmeyerA, Gereke M, Rudalska R, Potapova A et al: Senescence surveillance ofpre-malignant hepatocytes limits liver cancer development. Nature2011,479(7374):547-551.
158. Wiemann SU, Satyanarayana A, Tsahuridu M, Tillmann HL, Zender L,Klempnauer J, Flemming P, Franco S, Blasco MA, Manns MP et al:Hepatocyte telomere shortening and senescence are general markers of humanliver cirrhosis. FASEB J2002,16(9):935-942.
159. Wang Z, Lin H, Hua F, Hu ZW: Repairing DNA damage by XRCC6/KU70reverses TLR4-deficiency-worsened HCC development via restoringsenescence and autophagic flux. Autophagy2013,9(6):925-927.
160. Iredale JP: Models of liver fibrosis: exploring the dynamic nature ofinflammation and repair in a solid organ. J Clin Invest2007,117(3):539-548.
161. Ramakrishna G, Anwar T, Angara RK, Chatterjee N, Kiran S, Singh S: Role ofcellular senescence in hepatic wound healing and carcinogenesis. Eur J CellBiol2012,91(10):739-747.
162. Timchenko NA: Aging and liver regeneration. Trends Endocrinol Metab2009,20(4):171-176.
2. Llovet JM, Bruix J: Molecular targeted therapies in hepatocellular carcinoma.Hepatology2008,48(4):1312-1327.
3. Arciero CA, Sigurdson ER: Liver-directed therapies for patients with primaryliver cancer and hepatic metastases. Curr Treat Options Oncol2006,7(5):399-409.
4. Roskams T, Katoonizadeh A, Komuta M: Hepatic progenitor cells: an update.Clin Liver Dis2010,14(4):705-718.
5. Roskams TA, Theise ND, Balabaud C, Bhagat G, Bhathal PS, Bioulac-Sage P,Brunt EM, Crawford JM, Crosby HA, Desmet V et al: Nomenclature of thefiner branches of the biliary tree: canals, ductules, and ductular reactions inhuman livers. Hepatology2004,39(6):1739-1745.
6. Knight B, Matthews VB, Olynyk JK, Yeoh GC: Jekyll and Hyde: evolvingperspectives on the function and potential of the adult liver progenitor (oval)cell. Bioessays2005,27(11):1192-1202.
7. Libbrecht L, Desmet V, Van Damme B, Roskams T: Theimmunohistochemical phenotype of dysplastic foci in human liver: correlationwith putative progenitor cells. J Hepatol2000,33(1):76-84.
8. Durnez A, Verslype C, Nevens F, Fevery J, Aerts R, Pirenne J, Lesaffre E,Libbrecht L, Desmet V, Roskams T: The clinicopathological and prognosticrelevance of cytokeratin7and19expression in hepatocellular carcinoma. Apossible progenitor cell origin. Histopathology2006,49(2):138-151.
9. Yang XR, Xu Y, Yu B, Zhou J, Qiu SJ, Shi GM, Zhang BH, Wu WZ, Shi YH,Wu B et al: High expression levels of putative hepatic stem/progenitor cellbiomarkers related to tumour angiogenesis and poor prognosis ofhepatocellular carcinoma. Gut2010,59(7):953-962.
10. Roskams T: Liver stem cells and their implication in hepatocellular andcholangiocarcinoma. Oncogene2006,25(27):3818-3822.
11. Roskams T, Desmet V: Ductular reaction and its diagnostic significance.Semin Diagn Pathol1998,15(4):259-269.
12. Park YN, Kojiro M, Di Tommaso L, Dhillon AP, Kondo F, Nakano M,Sakamoto M, Theise ND, Roncalli M: Ductular reaction is helpful in definingearly stromal invasion, small hepatocellular carcinomas, and dysplasticnodules. Cancer2007,109(5):915-923.
13. Bateman AC, Hubscher SG: Cytokeratin expression as an aid to diagnosis inmedical liver biopsies. Histopathology2010,56(4):415-425.
14. Knight B, Matthews VB, Akhurst B, Croager EJ, Klinken E, Abraham LJ,Olynyk JK, Yeoh G: Liver inflammation and cytokine production, but notacute phase protein synthesis, accompany the adult liver progenitor (oval) cellresponse to chronic liver injury. Immunol Cell Biol2005,83(4):364-374.
15. Freeman A, Hamid S, Morris L, Vowler S, Rushbrook S, Wight DG, ColemanN, Alexander GJ: Improved detection of hepatocyte proliferation usingantibody to the pre-replication complex: an association with hepatic fibrosisand viral replication in chronic hepatitis C virus infection. J Viral Hepat2003,10(5):345-350.
16. Mantovani A: Cancer: Inflaming metastasis. Nature2009,457(7225):36-37.
17. Libbrecht L, Desmet V, Van Damme B, Roskams T: Deep intralobularextension of human hepatic 'progenitor cells' correlates with parenchymalinflammation in chronic viral hepatitis: can 'progenitor cells' migrate? J Pathol2000,192(3):373-378.
18. Kuang DM, Peng C, Zhao Q, Wu Y, Chen MS, Zheng L: Activated monocytesin peritumoral stroma of hepatocellular carcinoma promote expansion ofmemory T helper17cells. Hepatology2010,51(1):154-164.
19. Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, andcancer stem cells. Nature2001,414(6859):105-111.
20. Schmelzer E, Reid LM: EpCAM expression in normal, non-pathologicaltissues. Front Biosci2008,13:3096-3100.
21. Lu TY, Lu RM, Liao MY, Yu J, Chung CH, Kao CF, Wu HC: Epithelial celladhesion molecule regulation is associated with the maintenance of theundifferentiated phenotype of human embryonic stem cells. J Biol Chem2010,285(12):8719-8732.
22. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, Jia H, Ye Q, QinLX, Wauthier E et al: EpCAM-positive hepatocellular carcinoma cells aretumor-initiating cells with stem/progenitor cell features. Gastroenterology2009,136(3):1012-1024.
23. Murakata A, Tanaka S, Mogushi K, Yasen M, Noguchi N, Irie T, Kudo A,Nakamura N, Tanaka H, Arii S: Gene expression signature of the grossmorphology in hepatocellular carcinoma. Ann Surg2011,253(1):94-100.
24. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S,Sugawara Y, Minagawa M, Takayama T, Kawasaki S et al: Risk factorscontributing to early and late phase intrahepatic recurrence of hepatocellularcarcinoma after hepatectomy. J Hepatol2003,38(2):200-207.
25. Llovet JM: Updated treatment approach to hepatocellular carcinoma. JGastroenterol2005,40(3):225-235.
26. Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA,Giulini SM: Early and late recurrence after liver resection for hepatocellularcarcinoma: prognostic and therapeutic implications. Ann Surg2006,243(2):229-235.
27. Poon RT: Prevention of recurrence after resection of hepatocellular carcinoma:a daunting challenge. Hepatology2011,54(3):757-759.
28. Desmet VJ: Modulation of the liver in cholestasis. J Gastroenterol Hepatol1992,7(3):313-323.
29. Liu Z, Sakamoto T, Ezure T, Yokomuro S, Murase N, Michalopoulos G,Demetris AJ: Interleukin-6, hepatocyte growth factor, and their receptors inbiliary epithelial cells during a type I ductular reaction in mice: interactionsbetween the periductal inflammatory and stromal cells and the biliaryepithelium. Hepatology1998,28(5):1260-1268.
30. Roskams TA, Libbrecht L, Desmet VJ: Progenitor cells in diseased humanliver. Semin Liver Dis2003,23(4):385-396.
31. Bird TG, Lorenzini S, Forbes SJ: Activation of stem cells in hepatic diseases.Cell Tissue Res2008,331(1):283-300.
32. Lu XY, Xi T, Lau WY, Dong H, Zhu Z, Shen F, Wu MC, Cong WM:Hepatocellular Carcinoma Expressing Cholangiocyte Phenotype Is a NovelSubtype with Highly Aggressive Behavior. Ann Surg Oncol2011.
33. Li YW, Qiu SJ, Fan J, Zhou J, Gao Q, Xiao YS, Xu YF: Intratumoralneutrophils: a poor prognostic factor for hepatocellular carcinoma followingresection. J Hepatol2011,54(3):497-505.
34. Lopez PM, Villanueva A, Llovet JM: Systematic review: evidence-basedmanagement of hepatocellular carcinoma--an updated analysis of randomizedcontrolled trials. Aliment Pharmacol Ther2006,23(11):1535-1547.
35. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A,Gupta S, Moore J, Wrobel MJ, Lerner J et al: Gene expression in fixed tissuesand outcome in hepatocellular carcinoma. N Engl J Med2008,359(19):1995-2004.
36. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H,Desmet V, Korb G, MacSween RN et al: Histological grading and staging ofchronic hepatitis. J Hepatol1995,22(6):696-699.
37. Zhou H, Rogler LE, Teperman L, Morgan G, Rogler CE: Identification ofhepatocytic and bile ductular cell lineages and candidate stem cells in bipolarductular reactions in cirrhotic human liver. Hepatology2007,45(3):716-724.
38. Svegliati-Baroni G, Faraci G, Fabris L, Saccomanno S, Cadamuro M,Pierantonelli I, Trozzi L, Bugianesi E, Guido M, Strazzabosco M et al: Insulinresistance and necroinflammation drives ductular reaction andepithelial-mesenchymal transition in chronic hepatitis C. Gut2011,60(1):108-115.
39. Clouston AD, Powell EE, Walsh MJ, Richardson MM, Demetris AJ, JonssonJR: Fibrosis correlates with a ductular reaction in hepatitis C: roles of impairedreplication, progenitor cells and steatosis. Hepatology2005,41(4):809-818.
40. Richardson MM, Jonsson JR, Powell EE, Brunt EM, Neuschwander-Tetri BA,Bhathal PS, Dixon JB, Weltman MD, Tilg H, Moschen AR et al: Progressivefibrosis in nonalcoholic steatohepatitis: association with altered regenerationand a ductular reaction. Gastroenterology2007,133(1):80-90.
41. Fabris L, Cadamuro M, Guido M, Spirli C, Fiorotto R, Colledan M, Torre G,Alberti D, Sonzogni A, Okolicsanyi L et al: Analysis of liver repairmechanisms in Alagille syndrome and biliary atresia reveals a role for notchsignaling. Am J Pathol2007,171(2):641-653.
42. Tan J, Hytiroglou P, Wieczorek R, Park YN, Thung SN, Arias B, Theise ND:Immunohistochemical evidence for hepatic progenitor cells in liver diseases.Liver2002,22(5):365-373.
43. Napoli J, Bishop GA, McGuinness PH, Painter DM, McCaughan GW:Progressive liver injury in chronic hepatitis C infection correlates withincreased intrahepatic expression of Th1-associated cytokines. Hepatology1996,24(4):759-765.
44. Gochee PA, Jonsson JR, Clouston AD, Pandeya N, Purdie DM, Powell EE:Steatosis in chronic hepatitis C: association with increased messenger RNAexpression of collagen I, tumor necrosis factor-alpha and cytochrome P4502E1. J Gastroenterol Hepatol2003,18(4):386-392.
45. Fausto N: Liver regeneration and repair: hepatocytes, progenitor cells, andstem cells. Hepatology2004,39(6):1477-1487.
46. Kallis YN, Robson AJ, Fallowfield JA, Thomas HC, Alison MR, Wright NA,Goldin RD, Iredale JP, Forbes SJ: Remodelling of extracellular matrix is arequirement for the hepatic progenitor cell response. Gut2011,60(4):525-533.
47. Deng H, Wang HF, Gao YB, Jin XL, Xiao JC: Hepatic progenitor cellrepresents a transitioning cell population between liver epithelium and stroma.Med Hypotheses2011,76(6):809-812.
48. Pritchard MT, Nagy LE: Hepatic fibrosis is enhanced and accompanied byrobust oval cell activation after chronic carbon tetrachloride administration toEgr-1-deficient mice. Am J Pathol2010,176(6):2743-2752.
49. Clouston AD, Jonsson JR, Powell EE: Hepatic progenitor cell-mediatedregeneration and fibrosis: chicken or egg? Hepatology2009,49(5):1424-1426.
50. Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer.Cell2010,140(6):883-899.
51. Qian BZ, Pollard JW: Macrophage diversity enhances tumor progression andmetastasis. Cell2010,141(1):39-51.
52. White E, Karp C, Strohecker AM, Guo Y, Mathew R: Role of autophagy insuppression of inflammation and cancer. Curr Opin Cell Biol2010,22(2):212-217.
53. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell2011,144(5):646-674.
54. Larue L, Bellacosa A: Epithelial-mesenchymal transition in development andcancer: role of phosphatidylinositol3' kinase/AKT pathways. Oncogene2005,24(50):7443-7454.
55. Jing Y, Han Z, Liu Y, Sun K, Zhang S, Jiang G, Li R, Gao L, Zhao X, Wu Det al: Mesenchymal stem cells in inflammation microenvironment accelerateshepatocellular carcinoma metastasis by inducing epithelial-mesenchymaltransition. PLoS One2012,7(8):e43272.
56. Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, Wu WZ,Wang L, Tang ZY, Sun HC: High expression of macrophagecolony-stimulating factor in peritumoral liver tissue is associated with poorsurvival after curative resection of hepatocellular carcinoma. J Clin Oncol2008,26(16):2707-2716.
57. Sell S: Stem cell origin of cancer and differentiation therapy. Crit Rev OncolHematol2004,51(1):1-28.
58. Sell S, Pierce GB: Maturation arrest of stem cell differentiation is a commonpathway for the cellular origin of teratocarcinomas and epithelial cancers. LabInvest1994,70(1):6-22.
59. Sell S: Alpha-fetoprotein, stem cells and cancer: how study of the productionof alpha-fetoprotein during chemical hepatocarcinogenesis led to reaffirmationof the stem cell theory of cancer. Tumour Biol2008,29(3):161-180.
60. Libbrecht L: Hepatic progenitor cells in human liver tumor development.World J Gastroenterol2006,12(39):6261-6265.
61. Sell S, Leffert HL: Liver cancer stem cells. J Clin Oncol2008,26(17):2800-2805.
62. Ziol M, Nault JC, Aout M, Barget N, Tepper M, Martin A, Trinchet JC,Ganne-Carrie N, Vicaut E, Beaugrand M et al: Intermediate hepatobiliary cellspredict an increased risk of hepatocarcinogenesis in patients with hepatitis Cvirus-related cirrhosis. Gastroenterology2010,139(1):335-343e332.
63. Yang XR, Xu Y, Shi GM, Fan J, Zhou J, Ji Y, Sun HC, Qiu SJ, Yu B, Gao Qet al: Cytokeratin10and Cytokeratin19: Predictive Markers for PoorPrognosis in Hepatocellular Carcinoma Patients after Curative Resection.Clinical Cancer Research2008,14(12):3850-3859.
64. Zhuang PY, Zhang JB, Zhu XD, Zhang W, Wu WZ, Tan YS, Hou J, Tang ZY,Qin LX, Sun HC: Two pathologic types of hepatocellular carcinoma withlymph node metastasis with distinct prognosis on the basis of CK19expression in tumor. Cancer2008,112(12):2740-2748.
65. Uenishi T, Kubo S, Yamamoto T, Shuto T, Ogawa M, Tanaka H, Tanaka S,Kaneda K, Hirohashi K: Cytokeratin19expression in hepatocellularcarcinoma predicts early postoperative recurrence. Cancer Sci2003,94(10):851-857.
66. Tsuchiya K, Komuta M, Yasui Y, Tamaki N, Hosokawa T, Ueda K, Kuzuya T,Itakura J, Nakanishi H, Takahashi Y et al: Expression of keratin19is relatedto high recurrence of hepatocellular carcinoma after radiofrequency ablation.Oncology2011,80(3-4):278-288.
67. Lowes KN, Brennan BA, Yeoh GC, Olynyk JK: Oval cell numbers in humanchronic liver diseases are directly related to disease severity. Am J Pathol1999,154(2):537-541.
68. Roskams T, De Vos R, Van Eyken P, Myazaki H, Van Damme B, Desmet V:Hepatic OV-6expression in human liver disease and rat experiments: evidencefor hepatic progenitor cells in man. J Hepatol1998,29(3):455-463.
69. Kimura O, Takahashi T, Ishii N, Inoue Y, Ueno Y, Kogure T, Fukushima K,Shiina M, Yamagiwa Y, Kondo Y et al: Characterization of the epithelial celladhesion molecule (EpCAM)+cell population in hepatocellular carcinomacell lines. Cancer Sci2010,101(10):2145-2155.
70. Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, Budhu A, ZanettiKA, Chen Y, Qin LX et al: EpCAM and alpha-fetoprotein expression definesnovel prognostic subtypes of hepatocellular carcinoma. Cancer Res2008,68(5):1451-1461.
71. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, Jia H, Ye Q, QinLX, Wauthier E: EpCAM-Positive Hepatocellular Carcinoma Cells AreTumor-Initiating Cells With Stem/Progenitor Cell Features. Gastroenterology2009,136(3):1012-1024.e1014.
72. Cantz T, Manns MP, Ott M: Stem cells in liver regeneration and therapy. CellTissue Res2008,331(1):271-282.
73. Roskams T: Liver stem cells and their implication in hepatocellular andcholangiocarcinoma. Oncogene2006,25(27):3818-3822.
74. Roskams T: Progenitor cell involvement in cirrhotic human liver diseases:from controversy to consensus. J Hepatol2003,39(3):431-434.
1. El-Serag HB: Hepatocellular carcinoma. N Engl J Med2011,365(12):1118-1127.
2. Ramakrishna G, Rastogi A, Trehanpati N, Sen B, Khosla R, Sarin SK: FromCirrhosis to Hepatocellular Carcinoma: New Molecular Insights onInflammation and Cellular Senescence. Liver Cancer2013,2(3-4):367-383.
3. Douarin NM: An experimental analysis of liver development. Med Biol1975,53(6):427-455.
4. Gualdi R, Bossard P, Zheng M, Hamada Y, Coleman JR, Zaret KS: Hepaticspecification of the gut endoderm in vitro: cell signaling and transcriptionalcontrol. Genes Dev1996,10(13):1670-1682.
5. Jung J, Zheng M, Goldfarb M, Zaret KS: Initiation of mammalian liverdevelopment from endoderm by fibroblast growth factors. Science1999,284(5422):1998-2003.
6. Rossi JM, Dunn NR, Hogan BL, Zaret KS: Distinct mesodermal signals,including BMPs from the septum transversum mesenchyme, are required incombination for hepatogenesis from the endoderm. Genes Dev2001,15(15):1998-2009.
7. Ober EA, Verkade H, Field HA, Stainier DY: Mesodermal Wnt2b signallingpositively regulates liver specification. Nature2006,442(7103):688-691.
8. Sosa-Pineda B, Wigle JT, Oliver G: Hepatocyte migration during liverdevelopment requires Prox1. Nat Genet2000,25(3):254-255.
9. Zaret K: Early liver differentiation: genetic potentiation and multilevel growthcontrol. Curr Opin Genet Dev1998,8(5):526-531.
10. Matsumoto K, Yoshitomi H, Rossant J, Zaret KS: Liver organogenesispromoted by endothelial cells prior to vascular function. Science2001,294(5542):559-563.
11. Kubota H, Reid LM: Clonogenic hepatoblasts, common precursors forhepatocytic and biliary lineages, are lacking classical major histocompatibilitycomplex class I antigen. Proc Natl Acad Sci U S A2000,97(22):12132-12137.
12. Suzuki A, Zheng Y, Kondo R, Kusakabe M, Takada Y, Fukao K, Nakauchi H,Taniguchi H: Flow-cytometric separation and enrichment of hepatic progenitorcells in the developing mouse liver. Hepatology2000,32(6):1230-1239.
13. Minguet S, Cortegano I, Gonzalo P, Martinez-Marin JA, de Andres B, Salas C,Melero D, Gaspar ML, Marcos MA: A population ofc-Kit(low)(CD45/TER119)-hepatic cell progenitors of11-day postcoitusmouse embryo liver reconstitutes cell-depleted liver organoids. J Clin Invest2003,112(8):1152-1163.
14. Tanimizu N, Nishikawa M, Saito H, Tsujimura T, Miyajima A: Isolation ofhepatoblasts based on the expression of Dlk/Pref-1. J Cell Sci2003,116(Pt9):1775-1786.
15. Floridon C, Jensen CH, Thorsen P, Nielsen O, Sunde L, Westergaard JG,Thomsen SG, Teisner B: Does fetal antigen1(FA1) identify cells withregenerative, endocrine and neuroendocrine potentials? A study of FA1inembryonic, fetal, and placental tissue and in maternal circulation.Differentiation2000,66(1):49-59.
16. Yanai H, Nakamura K, Hijioka S, Kamei A, Ikari T, Ishikawa Y, Shinozaki E,Mizunuma N, Hatake K, Miyajima A: Dlk-1, a cell surface antigen on foetalhepatic stem/progenitor cells, is expressed in hepatocellular, colon, pancreasand breast carcinomas at a high frequency. J Biochem2010,148(1):85-92.
17. Nierhoff D, Ogawa A, Oertel M, Chen YQ, Shafritz DA: Purification andcharacterization of mouse fetal liver epithelial cells with high in vivorepopulation capacity. Hepatology2005,42(1):130-139.
18. Tanaka M, Okabe M, Suzuki K, Kamiya Y, Tsukahara Y, Saito S, Miyajima A:Mouse hepatoblasts at distinct developmental stages are characterized byexpression of EpCAM and DLK1: drastic change of EpCAM expressionduring liver development. Mech Dev2009,126(8-9):665-676.
19. Dan YY, Riehle KJ, Lazaro C, Teoh N, Haque J, Campbell JS, Fausto N:Isolation of multipotent progenitor cells from human fetal liver capable ofdifferentiating into liver and mesenchymal lineages. Proc Natl Acad Sci U S A2006,103(26):9912-9917.
20. Schmelzer E, Zhang L, Bruce A, Wauthier E, Ludlow J, Yao HL, Moss N,Melhem A, McClelland R, Turner W et al: Human hepatic stem cells fromfetal and postnatal donors. J Exp Med2007,204(8):1973-1987.
21. Kakinuma S, Ohta H, Kamiya A, Yamazaki Y, Oikawa T, Okada K, NakauchiH: Analyses of cell surface molecules on hepatic stem/progenitor cells inmouse fetal liver. J Hepatol2009,51(1):127-138.
22. Antoniou A, Raynaud P, Cordi S, Zong Y, Tronche F, Stanger BZ, Jacquemin P,Pierreux CE, Clotman F, Lemaigre FP: Intrahepatic bile ducts developaccording to a new mode of tubulogenesis regulated by the transcription factorSOX9. Gastroenterology2009,136(7):2325-2333.
23. Clotman F, Jacquemin P, Plumb-Rudewiez N, Pierreux CE, Van der Smissen P,Dietz HC, Courtoy PJ, Rousseau GG, Lemaigre FP: Control of liver cell fatedecision by a gradient of TGF beta signaling modulated by Onecuttranscription factors. Genes Dev2005,19(16):1849-1854.
24. Suzuki K, Tanaka M, Watanabe N, Saito S, Nonaka H, Miyajima A: p75Neurotrophin receptor is a marker for precursors of stellate cells and portalfibroblasts in mouse fetal liver. Gastroenterology2008,135(1):270-281e273.
25. Tanimizu N, Miyajima A: Notch signaling controls hepatoblast differentiationby altering the expression of liver-enriched transcription factors. J Cell Sci2004,117(Pt15):3165-3174.
26. Zong Y, Panikkar A, Xu J, Antoniou A, Raynaud P, Lemaigre F, Stanger BZ:Notch signaling controls liver development by regulating biliarydifferentiation. Development2009,136(10):1727-1739.
27. Tanaka M, Itoh T, Tanimizu N, Miyajima A: Liver stem/progenitor cells: theircharacteristics and regulatory mechanisms. J Biochem2011,149(3):231-239.
28. Geisler F, Nagl F, Mazur PK, Lee M, Zimber-Strobl U, Strobl LJ, Radtke F,Schmid RM, Siveke JT: Liver-specific inactivation of Notch2, but not Notch1,compromises intrahepatic bile duct development in mice. Hepatology2008,48(2):607-616.
29. Lozier J, McCright B, Gridley T: Notch signaling regulates bile ductmorphogenesis in mice. PLoS One2008,3(3):e1851.
30. Sparks EE, Huppert KA, Brown MA, Washington MK, Huppert SS: Notchsignaling regulates formation of the three-dimensional architecture ofintrahepatic bile ducts in mice. Hepatology2010,51(4):1391-1400.
31. Tchorz JS, Kinter J, Muller M, Tornillo L, Heim MH, Bettler B: Notch2signaling promotes biliary epithelial cell fate specification and tubulogenesisduring bile duct development in mice. Hepatology2009,50(3):871-879.
32. Clotman F, Lannoy VJ, Reber M, Cereghini S, Cassiman D, Jacquemin P,Roskams T, Rousseau GG, Lemaigre FP: The onecut transcription factorHNF6is required for normal development of the biliary tract. Development2002,129(8):1819-1828.
33. Coffinier C, Gresh L, Fiette L, Tronche F, Schutz G, Babinet C, Pontoglio M,Yaniv M, Barra J: Bile system morphogenesis defects and liver dysfunctionupon targeted deletion of HNF1beta. Development2002,129(8):1829-1838.
34. Hunter MP, Wilson CM, Jiang X, Cong R, Vasavada H, Kaestner KH, BogueCW: The homeobox gene Hhex is essential for proper hepatoblastdifferentiation and bile duct morphogenesis. Dev Biol2007,308(2):355-367.
35. Kodama Y, Hijikata M, Kageyama R, Shimotohno K, Chiba T: The role ofnotch signaling in the development of intrahepatic bile ducts.Gastroenterology2004,127(6):1775-1786.
36. Krupczak-Hollis K, Wang X, Kalinichenko VV, Gusarova GA, Wang IC,Dennewitz MB, Yoder HM, Kiyokawa H, Kaestner KH, Costa RH: The mouseForkhead Box m1transcription factor is essential for hepatoblast mitosis anddevelopment of intrahepatic bile ducts and vessels during liver morphogenesis.Dev Biol2004,276(1):74-88.
37. Li Z, White P, Tuteja G, Rubins N, Sackett S, Kaestner KH: Foxa1and Foxa2regulate bile duct development in mice. J Clin Invest2009,119(6):1537-1545.
38. Oikawa T, Kamiya A, Kakinuma S, Zeniya M, Nishinakamura R, Tajiri H,Nakauchi H: Sall4regulates cell fate decision in fetal hepatic stem/progenitorcells. Gastroenterology2009,136(3):1000-1011.
39. Suzuki A, Sekiya S, Buscher D, Izpisua Belmonte JC, Taniguchi H: Tbx3controls the fate of hepatic progenitor cells in liver development bysuppressing p19ARF expression. Development2008,135(9):1589-1595.
40. Raynaud P, Carpentier R, Antoniou A, Lemaigre FP: Biliary differentiationand bile duct morphogenesis in development and disease. Int J Biochem CellBiol2011,43(2):245-256.
41. Tanimizu N, Miyajima A, Mostov KE: Liver progenitor cells developcholangiocyte-type epithelial polarity in three-dimensional culture. Mol BiolCell2007,18(4):1472-1479.
42. Tanimizu N, Miyajima A, Mostov KE: Liver progenitor cells fold up a cellmonolayer into a double-layered structure during tubular morphogenesis. MolBiol Cell2009,20(9):2486-2494.
43. Tanimizu N, Saito H, Mostov K, Miyajima A: Long-term culture of hepaticprogenitors derived from mouse Dlk+hepatoblasts. J Cell Sci2004,117(Pt26):6425-6434.
44. Strick-Marchand H, Morosan S, Charneau P, Kremsdorf D, Weiss MC:Bipotential mouse embryonic liver stem cell lines contribute to liverregeneration and differentiate as bile ducts and hepatocytes. Proc Natl AcadSci U S A2004,101(22):8360-8365.
45. Asahina K, Tsai SY, Li P, Ishii M, Maxson RE, Jr., Sucov HM, Tsukamoto H:Mesenchymal origin of hepatic stellate cells, submesothelial cells, andperivascular mesenchymal cells during mouse liver development. Hepatology2009,49(3):998-1011.
46. Onitsuka I, Tanaka M, Miyajima A: Characterization and functional analysesof hepatic mesothelial cells in mouse liver development. Gastroenterology2010,138(4):1525-1535,1535e1521-1526.
47. Ijpenberg A, Perez-Pomares JM, Guadix JA, Carmona R, Portillo-Sanchez V,Macias D, Hohenstein P, Miles CM, Hastie ND, Munoz-Chapuli R: Wt1andretinoic acid signaling are essential for stellate cell development and livermorphogenesis. Dev Biol2007,312(1):157-170.
48. Kamiya A, Kinoshita T, Ito Y, Matsui T, Morikawa Y, Senba E, Nakashima K,Taga T, Yoshida K, Kishimoto T et al: Fetal liver development requires aparacrine action of oncostatin M through the gp130signal transducer. EMBO J1999,18(8):2127-2136.
49. Kinoshita T, Sekiguchi T, Xu MJ, Ito Y, Kamiya A, Tsuji K, Nakahata T,Miyajima A: Hepatic differentiation induced by oncostatin M attenuates fetalliver hematopoiesis. Proc Natl Acad Sci U S A1999,96(13):7265-7270.
50. Michalopoulos GK: Liver regeneration after partial hepatectomy: criticalanalysis of mechanistic dilemmas. Am J Pathol2010,176(1):2-13.
51. Overturf K, al-Dhalimy M, Ou CN, Finegold M, Grompe M: Serialtransplantation reveals the stem-cell-like regenerative potential of adult mousehepatocytes. Am J Pathol1997,151(5):1273-1280.
52. Alison MR, Golding MH, Sarraf CE: Pluripotential liver stem cells: facultativestem cells located in the biliary tree. Cell Prolif1996,29(7):373-402.
53. Roskams TA, Theise ND, Balabaud C, Bhagat G, Bhathal PS, Bioulac-Sage P,Brunt EM, Crawford JM, Crosby HA, Desmet V et al: Nomenclature of thefiner branches of the biliary tree: canals, ductules, and ductular reactions inhuman livers. Hepatology2004,39(6):1739-1745.
54. Theise ND, Saxena R, Portmann BC, Thung SN, Yee H, Chiriboga L, KumarA, Crawford JM: The canals of Hering and hepatic stem cells in humans.Hepatology1999,30(6):1425-1433.
55. Farber E: Similarities in the sequence of early histological changes induced inthe liver of the rat by ethionine,2-acetylamino-fluorene, and3'-methyl-4-dimethylaminoazobenzene. Cancer Res1956,16(2):142-148.
56. Paku S, Schnur J, Nagy P, Thorgeirsson SS: Origin and structural evolution ofthe early proliferating oval cells in rat liver. Am J Pathol2001,158(4):1313-1323.
57. Petersen BE, Bowen WC, Patrene KD, Mars WM, Sullivan AK, Murase N,Boggs SS, Greenberger JS, Goff JP: Bone marrow as a potential source ofhepatic oval cells. Science1999,284(5417):1168-1170.
58. Fausto N: Liver regeneration and repair: hepatocytes, progenitor cells, andstem cells. Hepatology2004,39(6):1477-1487.
59. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, Mikaelyan A,Roberts LR, Demetris AJ, Sun Z et al: A novel prognostic subtype of humanhepatocellular carcinoma derived from hepatic progenitor cells. Nat Med2006,12(4):410-416.
60. Evarts RP, Nagy P, Marsden E, Thorgeirsson SS: A precursor-productrelationship exists between oval cells and hepatocytes in rat liver.Carcinogenesis1987,8(11):1737-1740.
61. Laishes BA, Rolfe PB: Search for endogenous liver colony-forming units inF344rats given a two-thirds hepatectomy during short-term feeding of2-acetylaminofluorene. Cancer Res1981,41(5):1731-1741.
62. Akhurst B, Croager EJ, Farley-Roche CA, Ong JK, Dumble ML, Knight B,Yeoh GC: A modified choline-deficient, ethionine-supplemented diet protocoleffectively induces oval cells in mouse liver. Hepatology2001,34(3):519-522.
63. Preisegger KH, Factor VM, Fuchsbichler A, Stumptner C, Denk H,Thorgeirsson SS: Atypical ductular proliferation and its inhibition bytransforming growth factor beta1in the3,5-diethoxycarbonyl-1,4-dihydrocollidine mouse model for chronic alcoholicliver disease. Lab Invest1999,79(2):103-109.
64. Wang X, Foster M, Al-Dhalimy M, Lagasse E, Finegold M, Grompe M: Theorigin and liver repopulating capacity of murine oval cells. Proc Natl Acad SciU S A2003,100Suppl1:11881-11888.
65. Yovchev MI, Grozdanov PN, Joseph B, Gupta S, Dabeva MD: Novel hepaticprogenitor cell surface markers in the adult rat liver. Hepatology2007,45(1):139-149.
66. Yovchev MI, Grozdanov PN, Zhou H, Racherla H, Guha C, Dabeva MD:Identification of adult hepatic progenitor cells capable of repopulating injuredrat liver. Hepatology2008,47(2):636-647.
67. Suzuki A, Sekiya S, Onishi M, Oshima N, Kiyonari H, Nakauchi H, TaniguchiH: Flow cytometric isolation and clonal identification of self-renewingbipotent hepatic progenitor cells in adult mouse liver. Hepatology2008,48(6):1964-1978.
68. Okabe M, Tsukahara Y, Tanaka M, Suzuki K, Saito S, Kamiya Y, Tsujimura T,Nakamura K, Miyajima A: Potential hepatic stem cells reside in EpCAM+cells of normal and injured mouse liver. Development2009,136(11):1951-1960.
69. Fougere-Deschatrette C, Imaizumi-Scherrer T, Strick-Marchand H, Morosan S,Charneau P, Kremsdorf D, Faust DM, Weiss MC: Plasticity of hepatic celldifferentiation: bipotential adult mouse liver clonal cell lines competent todifferentiate in vitro and in vivo. Stem Cells2006,24(9):2098-2109.
70. Kamiya A, Kakinuma S, Yamazaki Y, Nakauchi H: Enrichment and clonalculture of progenitor cells during mouse postnatal liver development in mice.Gastroenterology2009,137(3):1114-1126,1126e1111-1114.
71. Knight B, Akhurst B, Matthews VB, Ruddell RG, Ramm GA, Abraham LJ,Olynyk JK, Yeoh GC: Attenuated liver progenitor (oval) cell and fibrogenicresponses to the choline deficient, ethionine supplemented diet in the BALB/cinbred strain of mice. J Hepatol2007,46(1):134-141.
72. Strick-Marchand H, Masse GX, Weiss MC, Di Santo JP: Lymphocytes supportoval cell-dependent liver regeneration. J Immunol2008,181(4):2764-2771.
73. Akhurst B, Matthews V, Husk K, Smyth MJ, Abraham LJ, Yeoh GC:Differential lymphotoxin-beta and interferon gamma signaling during mouseliver regeneration induced by chronic and acute injury. Hepatology2005,41(2):327-335.
74. Knight B, Yeoh GC, Husk KL, Ly T, Abraham LJ, Yu C, Rhim JA, Fausto N:Impaired preneoplastic changes and liver tumor formation in tumor necrosisfactor receptor type1knockout mice. J Exp Med2000,192(12):1809-1818.
75. Jakubowski A, Ambrose C, Parr M, Lincecum JM, Wang MZ, Zheng TS,Browning B, Michaelson JS, Baetscher M, Wang B et al: TWEAK inducesliver progenitor cell proliferation. J Clin Invest2005,115(9):2330-2340.
76. Tirnitz-Parker JE, Viebahn CS, Jakubowski A, Klopcic BR, Olynyk JK, YeohGC, Knight B: Tumor necrosis factor-like weak inducer of apoptosis is amitogen for liver progenitor cells. Hepatology2010,52(1):291-302.
77. Yovchev MI, Zhang J, Neufeld DS, Grozdanov PN, Dabeva MD: Thymus cellantigen-1-expressing cells in the oval cell compartment. Hepatology2009,50(2):601-611.
78. Apte U, Thompson MD, Cui S, Liu B, Cieply B, Monga SP: Wnt/beta-cateninsignaling mediates oval cell response in rodents. Hepatology2008,47(1):288-295.
79. Hu M, Kurobe M, Jeong YJ, Fuerer C, Ghole S, Nusse R, Sylvester KG:Wnt/beta-catenin signaling in murine hepatic transit amplifying progenitorcells. Gastroenterology2007,133(5):1579-1591.
80. Itoh T, Kamiya Y, Okabe M, Tanaka M, Miyajima A: Inducible expression ofWnt genes during adult hepatic stem/progenitor cell response. FEBS Lett2009,583(4):777-781.
81. Yang W, Yan HX, Chen L, Liu Q, He YQ, Yu LX, Zhang SH, Huang DD, TangL, Kong XN et al: Wnt/beta-catenin signaling contributes to activation ofnormal and tumorigenic liver progenitor cells. Cancer Res2008,68(11):4287-4295.
82. Yang XR, Xu Y, Yu B, Zhou J, Qiu SJ, Shi GM, Zhang BH, Wu WZ, Shi YH,Wu B et al: High expression levels of putative hepatic stem/progenitor cellbiomarkers related to tumour angiogenesis and poor prognosis ofhepatocellular carcinoma. Gut2010,59(7):953-962.
83. Yeh CT, Kuo CJ, Lai MW, Chen TC, Lin CY, Yeh TS, Lee WC:CD133-positive hepatocellular carcinoma in an area endemic for hepatitis Bvirus infection. BMC Cancer2009,9:324.
84. Kim H, Choi GH, Na DC, Ahn EY, Kim GI, Lee JE, Cho JY, Yoo JE, Choi JS,Park YN: Human hepatocellular carcinomas with "Stemness"-related markerexpression: keratin19expression and a poor prognosis. Hepatology2011,54(5):1707-1717.
85. Wu PC, Fang JW, Lau VK, Lai CL, Lo CK, Lau JY: Classification ofhepatocellular carcinoma according to hepatocellular and biliarydifferentiation markers. Clinical and biological implications. Am J Pathol1996,149(4):1167-1175.
86. Durnez A, Verslype C, Nevens F, Fevery J, Aerts R, Pirenne J, Lesaffre E,Libbrecht L, Desmet V, Roskams T: The clinicopathological and prognosticrelevance of cytokeratin7and19expression in hepatocellular carcinoma. Apossible progenitor cell origin. Histopathology2006,49(2):138-151.
87. Woo HG, Lee JH, Yoon JH, Kim CY, Lee HS, Jang JJ, Yi NJ, Suh KS, Lee KU,Park ES et al: Identification of a cholangiocarcinoma-like gene expression traitin hepatocellular carcinoma. Cancer Res2010,70(8):3034-3041.
88. Cai X, Zhai J, Kaplan DE, Zhang Y, Zhou L, Chen X, Qian G, Zhao Q, Li Y,Gao L et al: Background progenitor activation is associated with recurrenceafter hepatectomy of combined hepatocellular-cholangiocarcinoma.Hepatology2012,56(5):1804-1816.
89. Tsuchiya A, Kamimura H, Tamura Y, Takamura M, Yamagiwa S, Suda T,Nomoto M, Aoyagi Y: Hepatocellular carcinoma with progenitor cell featuresdistinguishable by the hepatic stem/progenitor cell marker NCAM. CancerLett2011,309(1):95-103.
90. Oliva J, French BA, Qing X, French SW: The identification of stem cells inhuman liver diseases and hepatocellular carcinoma. Exp Mol Pathol2010,88(3):331-340.
91. Ziol M, Nault JC, Aout M, Barget N, Tepper M, Martin A, Trinchet JC,Ganne-Carrie N, Vicaut E, Beaugrand M et al: Intermediate hepatobiliary cellspredict an increased risk of hepatocarcinogenesis in patients with hepatitis Cvirus-related cirrhosis. Gastroenterology2010,139(1):335-343e332.
92. Lee TK, Castilho A, Ma S, Ng IO: Liver cancer stem cells: implications for anew therapeutic target. Liver Int2009,29(7):955-965.
93. Chiba T, Kamiya A, Yokosuka O, Iwama A: Cancer stem cells inhepatocellular carcinoma: Recent progress and perspective. Cancer Lett2009,286(2):145-153.
94. Lee TK, Cheung VC, Ng IO: Liver tumor-initiating cells as a therapeutictarget for hepatocellular carcinoma. Cancer Lett2013,338(1):101-109.
95. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell2011,144(5):646-674.
96. Mueller K: Inflammation. Inflammation's yin-yang. Introduction. Science2013,339(6116):155.
97. Crispe IN: The liver as a lymphoid organ. Annu Rev Immunol2009,27:147-163.
98. Liaskou E, Wilson DV, Oo YH: Innate immune cells in liver inflammation.Mediators Inflamm2012,2012:949157.
99. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S,Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y: NF-kappaBfunctions as a tumour promoter in inflammation-associated cancer. Nature2004,431(7007):461-466.
100. Haybaeck J, Zeller N, Wolf MJ, Weber A, Wagner U, Kurrer MO, Bremer J,Iezzi G, Graf R, Clavien PA et al: A lymphotoxin-driven pathway tohepatocellular carcinoma. Cancer Cell2009,16(4):295-308.
101. Liu P, Kimmoun E, Legrand A, Sauvanet A, Degott C, Lardeux B, Bernuau D:Activation of NF-kappa B, AP-1and STAT transcription factors is a frequentand early event in human hepatocellular carcinomas. J Hepatol2002,37(1):63-71.
102. Luedde T, Schwabe RF: NF-kappaB in the liver--linking injury, fibrosis andhepatocellular carcinoma. Nat Rev Gastroenterol Hepatol2011,8(2):108-118.
103. He G, Yu GY, Temkin V, Ogata H, Kuntzen C, Sakurai T, Sieghart W,Peck-Radosavljevic M, Leffert HL, Karin M: Hepatocyte IKKbeta/NF-kappaBinhibits tumor promotion and progression by preventing oxidativestress-driven STAT3activation. Cancer Cell2010,17(3):286-297.
104. He G, Karin M: NF-kappaB and STAT3-key players in liver inflammationand cancer. Cell Res2011,21(1):159-168.
105. Das M, Sabio G, Jiang F, Rincon M, Flavell RA, Davis RJ: Induction ofhepatitis by JNK-mediated expression of TNF-alpha. Cell2009,136(2):249-260.
106. Das M, Garlick DS, Greiner DL, Davis RJ: The role of JNK in thedevelopment of hepatocellular carcinoma. Genes Dev2011,25(6):634-645.
107. Han MS, Jung DY, Morel C, Lakhani SA, Kim JK, Flavell RA, Davis RJ: JNKexpression by macrophages promotes obesity-induced insulin resistance andinflammation. Science2013,339(6116):218-222.
108. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M:Gender disparity in liver cancer due to sex differences in MyD88-dependentIL-6production. Science2007,317(5834):121-124.
109. Prieto J: Inflammation, HCC and sex: IL-6in the centre of the triangle. JHepatol2008,48(2):380-381.
110. Yang X, Schadt EE, Wang S, Wang H, Arnold AP, Ingram-Drake L, Drake TA,Lusis AJ: Tissue-specific expression and regulation of sexually dimorphicgenes in mice. Genome Res2006,16(8):995-1004.
111. Waxman DJ, Celenza JL: Sexual dimorphism of hepatic gene expression:novel biological role of KRAB zinc finger repressors revealed. Genes Dev2003,17(21):2607-2613.
112. Pinheiro I, Dejager L, Libert C: X-chromosome-located microRNAs inimmunity: might they explain male/female differences? The Xchromosome-genomic context may affect X-located miRNAs and downstreamsignaling, thereby contributing to the enhanced immune response of females.Bioessays2011,33(11):791-802.
113. Ingersoll MA, Platt AM, Potteaux S, Randolph GJ: Monocyte trafficking inacute and chronic inflammation. Trends Immunol2011,32(10):470-477.
114. Tacke F: Functional role of intrahepatic monocyte subsets for the progressionof liver inflammation and liver fibrosis in vivo. Fibrogenesis Tissue Repair2012,5Suppl1:S27.
115. Zimmermann HW, Seidler S, Nattermann J, Gassler N, Hellerbrand C,Zernecke A, Tischendorf JJ, Luedde T, Weiskirchen R, Trautwein C et al:Functional contribution of elevated circulating and hepatic non-classicalCD14CD16monocytes to inflammation and human liver fibrosis. PLoS One2010,5(6):e11049.
116. Karlmark KR, Weiskirchen R, Zimmermann HW, Gassler N, Ginhoux F,Weber C, Merad M, Luedde T, Trautwein C, Tacke F: Hepatic recruitment ofthe inflammatory Gr1+monocyte subset upon liver injury promotes hepaticfibrosis. Hepatology2009,50(1):261-274.
117. Deleve LD, Wang X, Guo Y: Sinusoidal endothelial cells prevent rat stellatecell activation and promote reversion to quiescence. Hepatology2008,48(3):920-930.
118. Connolly MK, Bedrosian AS, Malhotra A, Henning JR, Ibrahim J, Vera V,Cieza-Rubio NE, Hassan BU, Pachter HL, Cohen S et al: In hepatic fibrosis,liver sinusoidal endothelial cells acquire enhanced immunogenicity. JImmunol2010,185(4):2200-2208.
119. Brusko TM, Putnam AL, Bluestone JA: Human regulatory T cells: role inautoimmune disease and therapeutic opportunities. Immunol Rev2008,223:371-390.
120. Sasaki M, Ikeda H, Sawada S, Sato Y, Nakanuma Y: Naturally-occurringregulatory T cells are increased in inflamed portal tracts with cholangiopathyin primary biliary cirrhosis. J Clin Pathol2007,60(10):1102-1107.
121. Trehanpati N, Shrivastav S, Shivakumar B, Khosla R, Bhardwaj S, ChaturvediJ, Sukriti, Kumar B, Bose S, Mani Tripathi D et al: Analysis of Notch andTGF-beta Signaling Expression in Different Stages of Disease ProgressionDuring Hepatitis B Virus Infection. Clin Transl Gastroenterol2012,3:e23.
122. Martinon F, Mayor A, Tschopp J: The inflammasomes: guardians of the body.Annu Rev Immunol2009,27:229-265.
123. Schroder K, Tschopp J: The inflammasomes. Cell2010,140(6):821-832.
124. Davis BK, Wen H, Ting JP: The inflammasome NLRs in immunity,inflammation, and associated diseases. Annu Rev Immunol2011,29:707-735.
125. Boaru SG, Borkham-Kamphorst E, Tihaa L, Haas U, Weiskirchen R:Expression analysis of inflammasomes in experimental models ofinflammatory and fibrotic liver disease. J Inflamm (Lond)2012,9(1):49.
126. Szabo G, Csak T: Inflammasomes in liver diseases. J Hepatol2012,57(3):642-654.
127. Imaeda AB, Watanabe A, Sohail MA, Mahmood S, Mohamadnejad M,Sutterwala FS, Flavell RA, Mehal WZ: Acetaminophen-inducedhepatotoxicity in mice is dependent on Tlr9and the Nalp3inflammasome. JClin Invest2009,119(2):305-314.
128. Ganz M, Csak T, Nath B, Szabo G: Lipopolysaccharide induces and activatesthe Nalp3inflammasome in the liver. World J Gastroenterol2011,17(43):4772-4778.
129. Burdette D, Haskett A, Presser L, McRae S, Iqbal J, Waris G: Hepatitis C virusactivates interleukin-1beta via caspase-1-inflammasome complex. J Gen Virol2012,93(Pt2):235-246.
130. Petrasek J, Bala S, Csak T, Lippai D, Kodys K, Menashy V, Barrieau M, MinSY, Kurt-Jones EA, Szabo G: IL-1receptor antagonist amelioratesinflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest2012,122(10):3476-3489.
131. Svegliati-Baroni G, Faraci G, Fabris L, Saccomanno S, Cadamuro M,Pierantonelli I, Trozzi L, Bugianesi E, Guido M, Strazzabosco M et al: Insulinresistance and necroinflammation drives ductular reaction andepithelial-mesenchymal transition in chronic hepatitis C. Gut2011,60(1):108-115.
132. Falkowski O, An HJ, Ianus IA, Chiriboga L, Yee H, West AB, Theise ND:Regeneration of hepatocyte 'buds' in cirrhosis from intrabiliary stem cells. JHepatol2003,39(3):357-364.
133. Fausto N, Campbell JS, Riehle KJ: Liver regeneration. J Hepatol2012,57(3):692-694.
134. Gouw AS, Clouston AD, Theise ND: Ductular reactions in human liver:diversity at the interface. Hepatology2011,54(5):1853-1863.
135. Zhou H, Rogler LE, Teperman L, Morgan G, Rogler CE: Identification ofhepatocytic and bile ductular cell lineages and candidate stem cells in bipolarductular reactions in cirrhotic human liver. Hepatology2007,45(3):716-724.
136. Hanna RF, Aguirre DA, Kased N, Emery SC, Peterson MR, Sirlin CB:Cirrhosis-associated hepatocellular nodules: correlation of histopathologic andMR imaging features. Radiographics2008,28(3):747-769.
137. Lin WR, Lim SN, McDonald SA, Graham T, Wright VL, Peplow CL,Humphries A, Kocher HM, Wright NA, Dhillon AP et al: The histogenesis ofregenerative nodules in human liver cirrhosis. Hepatology2010,51(3):1017-1026.
138. Wright TL: Regenerating nodules--are they premalignant lesions? Hepatology1991,13(6):1254-1255.
139. Ng CH, Chan SW, Lee WK, Lai L, Lok KH, Li KK, Luk SH, Szeto ML:Hepatocarcinogenesis of regenerative and dysplastic nodules in Chinesepatients. Hong Kong Med J2011,17(1):11-19.
140. Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM: Role of themicroenvironment in the pathogenesis and treatment of hepatocellularcarcinoma. Gastroenterology2013,144(3):512-527.
141. Seitz HK, Stickel F: Risk factors and mechanisms of hepatocarcinogenesiswith special emphasis on alcohol and oxidative stress. Biol Chem2006,387(4):349-360.
142. Missiha SB, Ostrowski M, Heathcote EJ: Disease progression in chronichepatitis C: modifiable and nonmodifiable factors. Gastroenterology2008,134(6):1699-1714.
143. Bataller R, North KE, Brenner DA: Genetic polymorphisms and theprogression of liver fibrosis: a critical appraisal. Hepatology2003,37(3):493-503.
144. Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH,Shorthouse C, Purdie DM, Jonsson JR: Host genetic factors influence diseaseprogression in chronic hepatitis C. Hepatology2000,31(4):828-833.
145. Huang H, Shiffman ML, Friedman S, Venkatesh R, Bzowej N, Abar OT,Rowland CM, Catanese JJ, Leong DU, Sninsky JJ et al: A7gene signatureidentifies the risk of developing cirrhosis in patients with chronic hepatitis C.Hepatology2007,46(2):297-306.
146. Marcolongo M, Young B, Dal Pero F, Fattovich G, Peraro L, Guido M,Sebastiani G, Palu G, Alberti A: A seven-gene signature (cirrhosis risk score)predicts liver fibrosis progression in patients with initially mild chronichepatitis C. Hepatology2009,50(4):1038-1044.
147. Minouchi K, Kaneko S, Kobayashi K: Mutation of p53gene in regenerativenodules in cirrhotic liver. J Hepatol2002,37(2):231-239.
148. Calado RT, Brudno J, Mehta P, Kovacs JJ, Wu C, Zago MA, Chanock SJ,Boyer TD, Young NS: Constitutional telomerase mutations are genetic riskfactors for cirrhosis. Hepatology2011,53(5):1600-1607.
149. Hartmann D, Srivastava U, Thaler M, Kleinhans KN, N'Kontchou G,Scheffold A, Bauer K, Kratzer RF, Kloos N, Katz SF et al: Telomerase genemutations are associated with cirrhosis formation. Hepatology2011,53(5):1608-1617.
150. Di Gioia S, Bianchi P, Destro A, Grizzi F, Malesci A, Laghi L, Levrero M,Morabito A, Roncalli M: Quantitative evaluation of RASSF1A methylation inthe non-lesional, regenerative and neoplastic liver. BMC Cancer2006,6:89.
151. Um TH, Kim H, Oh BK, Kim MS, Kim KS, Jung G, Park YN: Aberrant CpGisland hypermethylation in dysplastic nodules and early HCC of hepatitis Bvirus-related human multistep hepatocarcinogenesis. J Hepatol2011,54(5):939-947.
152. Shay JW, Wright WE: Hayflick, his limit, and cellular ageing. Nat Rev MolCell Biol2000,1(1):72-76.
153. Yaswen P, Campisi J: Oncogene-induced senescence pathways weave anintricate tapestry. Cell2007,128(2):233-234.
154. Adams PD: Healing and hurting: molecular mechanisms, functions, andpathologies of cellular senescence. Mol Cell2009,36(1):2-14.
155. Krizhanovsky V, Yon M, Dickins RA, Hearn S, Simon J, Miething C, Yee H,Zender L, Lowe SW: Senescence of activated stellate cells limits liver fibrosis.Cell2008,134(4):657-667.
156. Schnabl B, Purbeck CA, Choi YH, Hagedorn CH, Brenner D: Replicativesenescence of activated human hepatic stellate cells is accompanied by apronounced inflammatory but less fibrogenic phenotype. Hepatology2003,37(3):653-664.
157. Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, HohmeyerA, Gereke M, Rudalska R, Potapova A et al: Senescence surveillance ofpre-malignant hepatocytes limits liver cancer development. Nature2011,479(7374):547-551.
158. Wiemann SU, Satyanarayana A, Tsahuridu M, Tillmann HL, Zender L,Klempnauer J, Flemming P, Franco S, Blasco MA, Manns MP et al:Hepatocyte telomere shortening and senescence are general markers of humanliver cirrhosis. FASEB J2002,16(9):935-942.
159. Wang Z, Lin H, Hua F, Hu ZW: Repairing DNA damage by XRCC6/KU70reverses TLR4-deficiency-worsened HCC development via restoringsenescence and autophagic flux. Autophagy2013,9(6):925-927.
160. Iredale JP: Models of liver fibrosis: exploring the dynamic nature ofinflammation and repair in a solid organ. J Clin Invest2007,117(3):539-548.
161. Ramakrishna G, Anwar T, Angara RK, Chatterjee N, Kiran S, Singh S: Role ofcellular senescence in hepatic wound healing and carcinogenesis. Eur J CellBiol2012,91(10):739-747.
162. Timchenko NA: Aging and liver regeneration. Trends Endocrinol Metab2009,20(4):171-176.